

REFINITIV

DELTA REPORT

10-Q

AVEANNA HEALTHCARE HOLDIN

10-Q - MARCH 30, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1432
--------------	------

 CHANGES	368
---	-----

 DELETIONS	651
---	-----

 ADDITIONS	413
---	-----

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended September March 30, 2023 2024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-40362

img24670257_0.jpg

Aveanna Healthcare Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

81-4717209

(I.R.S. Employer
Identification No.)

400 Interstate North Parkway SE, Atlanta, GA 30339

(Address of principal executive offices, including zip offices) (Zip code)



(770) 441-1580

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	AVAH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, **a** smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth
company

☐

E
m
er
gi
n
g
gr
o
w
th
c
o
m
p
a
n
y

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 3, 2023 May 3, 2024, the registrant had 190,733,153 192,378,711 shares of common stock, \$0.01 par value per share, outstanding.

Table of Contents

Page

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	
	Consolidated Balance Sheets as of September 30, 2023 March 30, 2024 (Unaudited) and December 31, 2022 December 30, 2023	2
	Consolidated Statements of Operations for the Three and Nine-Month Three-Month Periods Ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 (Unaudited)	3
	Consolidated Statements of Stockholders' (Deficit) Equity Deficit for the Three and Nine-Month Three-Month Periods Ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 (Unaudited)	4
	Consolidated Statements of Cash Flows for the Nine-Month Three-Month Periods Ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 (Unaudited)	5
	Notes to Consolidated Financial Statements (Unaudited)	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18 16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38 28
Item 4.	Controls and Procedures	38 28

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	40 30
Item 1A.	Risk Factors	40 30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40 30
Item 3.	Defaults Upon Senior Securities	40 30
Item 4.	Mine Safety Disclosures	40 30
Item 5.	Other Information	40 30
Item 6.	Exhibits	40 30
	SIGNATURES	
	Signatures	42 32

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial condition, business strategy, and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other similar expressions.

These statements are based on certain assumptions that we have made considering our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. As you read and consider this Quarterly Report on Form 10-Q, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties and assumptions. Many factors could affect our actual results and could cause actual results to differ materially from those expressed in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q are subject to risks that may cause actual results to differ materially from those expressed or implied in the forward-looking statements, including, but not limited to, the following risks:

- intense competition among home health, hospice and durable medical equipment companies;
- our ability to maintain relationships with existing patient referral sources;
- the possibility that our business, financial condition and results of operations may be materially adversely affected public health emergencies, such as a resurgence of the COVID-19 pandemic or variants of the virus; other public health emergencies;
- our ability to have services funded from third-party payers, including Medicare, Medicaid and private health insurance companies;
- changes to Medicare or Medicaid rates or methods governing Medicare or Medicaid payments, and the implementation of alternative payment models, including but not limited to Medicare Advantage, Managed Care Organization, managed Medicaid, and other forms of managed care;
- any downward pressure on reimbursement resulting from further proliferation of Medicare Advantage plans;
- our limited ability to control reimbursement rates received for our services;
- delays in collection or non-collection of our patient accounts receivable, particularly during the business integration process, or when transitioning between systems associated with clinical data collection and submission, as well as billing and collection systems;
- healthcare reform and other regulations;
- changes in the case-mix of our patients, as well as payer mix and payment methodologies;
- any reduction in net reimbursement if we do not effectively implement value-based care programs;
- our ability to attract and retain experienced employees and management personnel, and including both shortages of workforce and inflationary wage pressures;
- any failure to maintain the security and functionality of our information systems or to defend against or otherwise

prevent a cybersecurity attack or breach;

- our substantial indebtedness, which increases our vulnerability to general adverse economic and industry conditions and may limit our ability to pursue strategic alternatives and react to changes in our business and industry;
- our ability to identify, acquire, successfully integrate and obtain financing for strategic and accretive acquisitions;
- risks related to legal proceedings, claims and governmental inquiries given that the nature of our business exposes to various liability claims, which may exceed the level of our insurance coverage; and
- the other risks described under Part II, Item 1A, "Risk Factors" in this Quarterly Report on Form 10-Q and under the heading "Risk Factors" contained in our Annual Report on Form 10-K filed on **March 16, 2023** **March 14, 2024**.

Additionally, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Considering these risks, uncertainties and assumptions, the forward-looking statements contained in this Quarterly Report on Form 10-Q might not prove to be accurate and you should not place undue reliance upon them or otherwise rely upon them as predictions of future events. All forward-looking statements made by us in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES			
CONSOLIDATED BALANCE SHEETS			
(Amounts in thousands, except share and per share data)			
	As of		
	September 30, 2023	December 31, 2022	
	(Unaudited)		
ASSETS			
Current assets:			
Cash and cash equivalents	\$ 48,294	\$ 19,217	
Patient accounts receivable	235,668	221,237	

Receivables under insured programs	10,724	4,395
Prepaid expenses	12,352	15,089
Other current assets	11,207	9,813
Total current assets	318,245	269,751
Property and equipment, net	22,000	22,752
Operating lease right of use assets	51,789	54,601
Goodwill	1,054,552	1,159,688
Intangible assets, net	95,188	95,863
Receivables under insured programs	23,186	22,865
Other long-term assets	89,743	86,240
Total assets	\$ 1,654,703	\$ 1,711,760

LIABILITIES, DEFERRED RESTRICTED STOCK UNITS, AND STOCKHOLDERS' DEFICIT

Current liabilities:

Accounts payable and other accrued liabilities	\$ 36,527	\$ 44,624
Accrued payroll and employee benefits	75,588	43,836
Current portion of insurance reserves - insured programs	10,724	4,395
Current portion of insurance reserves	18,939	27,531
Securitization obligations	155,000	140,000
Current portion of long-term obligations	9,200	9,200
Current portion of operating lease liabilities	13,972	13,070
Other current liabilities	44,350	43,841
Total current liabilities	364,300	326,497
Revolving credit facility	-	-
Long-term obligations, less current portion	1,277,582	1,281,082
Long-term insurance reserves - insured programs	23,186	22,865
Long-term insurance reserves	44,291	35,470
Operating lease liabilities, less current portion	42,603	45,818
Deferred income taxes	4,419	3,844
Other long-term liabilities	1,900	359
Total liabilities	1,758,281	1,715,935
Commitments and contingencies (Note 11)		
Deferred restricted stock units	2,135	2,135

Stockholders' deficit:

Preferred stock, \$0.01 par value as of September 30, 2023 and December 31, 2022

5,000,000 shares authorized; none issued or outstanding - -

Common stock, \$0.01 par value, 1,000,000,000 shares authorized;

190,733,153 and 188,859,165 issued and outstanding, respectively 1,907 1,888

Additional paid-in capital 1,237,878 1,228,512

Accumulated deficit (1,345,498) (1,236,710)

Total stockholders' deficit (105,713) (6,310)

Total liabilities, deferred restricted stock units, and stockholders' deficit \$ 1,654,703 \$ 1,711,760

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

	As of	
	March 30, 2024	December 30, 2023
	(Unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 42,607	\$ 43,942
Patient accounts receivable	257,544	236,558
Receivables under insured programs	11,024	9,250
Prepaid expenses	16,030	15,684
Other current assets	8,831	9,452
Total current assets	336,036	314,886
Property and equipment, net	19,424	20,548
Operating lease right of use assets	47,686	49,499
Goodwill	1,054,552	1,054,552
Intangible assets, net	93,364	94,010
Receivables under insured programs	24,991	21,315
Other long-term assets	66,899	58,175
Total assets	\$ 1,642,952	\$ 1,612,985

LIABILITIES, DEFERRED RESTRICTED STOCK UNITS, AND STOCKHOLDERS' DEFICIT

Current liabilities:			
Accounts payable and other accrued liabilities	\$	43,175	\$ 30,130
Accrued payroll and employee benefits		68,953	67,160
Current portion of insurance reserves - insured programs		11,024	9,250
Current portion of insurance reserves		20,258	20,918
Securitization obligations		165,000	155,000
Current portion of long-term obligations		9,200	9,200
Current portion of operating lease liabilities		15,440	14,881
Other current liabilities		48,880	48,219
Total current liabilities		381,930	354,758
Revolving credit facility		-	-
Long-term obligations, less current portion		1,275,127	1,276,341
Long-term insurance reserves - insured programs		24,991	21,315
Long-term insurance reserves		46,629	40,290
Operating lease liabilities, less current portion		39,137	39,818
Deferred income taxes		5,473	4,859
Other long-term liabilities		3,803	3,039
Total liabilities		1,777,090	1,740,420
Commitments and contingencies (Note 10)			
Deferred restricted stock units		2,135	2,135
Stockholders' deficit:			
Preferred stock, \$0.01 par value as of March 30, 2024 and December 30, 2023			
5,000,000 shares authorized; none issued or outstanding		-	-
Common stock, \$0.01 par value, 1,000,000,000 shares authorized;			
192,378,711 and 190,733,153 issued and outstanding, respectively		1,923	1,907
Additional paid-in capital		1,244,210	1,239,757
Accumulated deficit		(1,382,406)	(1,371,234)
Total stockholders' deficit		(136,273)	(129,570)
Total liabilities, deferred restricted stock units, and stockholders' deficit	\$	1,642,952	\$ 1,612,985

The accompanying notes are an integral part of these unaudited consolidated financial statements.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data)

(Unaudited)

	For the three-month periods ended		For the nine-month periods ended	
	September 30, 2023	October 1, 2022	September 30, 2023	October 1, 2022
Revenue	\$ 478,010	\$ 443,009	\$ 1,416,368	\$ 1,336,498
Cost of revenue, excluding depreciation and amortization	330,746	308,426	969,384	912,046
Branch and regional administrative expenses	91,004	89,542	273,967	267,283
Corporate expenses	27,446	33,215	84,735	105,984
Goodwill impairment	105,136	-	105,136	470,207
Depreciation and amortization	2,962	4,917	10,494	16,774
Acquisition-related costs	428	-	466	69
Other operating (income) expense	(3,360)	2,122	(6,593)	1,953
Operating (loss) income	(76,352)	4,787	(21,221)	(437,818)
Interest income	50	164	238	369
Interest expense	(39,599)	(28,462)	(113,542)	(73,745)
Other income	14,143	45,140	27,124	86,523
(Loss) income before income taxes	(101,758)	21,629	(107,401)	(424,671)
Income tax (expense) benefit	(631)	2,669	(1,387)	416
Net (loss) income	\$ (102,389)	\$ 24,298	\$ (108,788)	\$ (424,255)
Net (loss) income per share:				
Net (loss) income per share, basic	\$ (0.54)	\$ 0.13	\$ (0.57)	\$ (2.29)
Weighted average shares of common stock outstanding, basic	189,139	186,113	189,632	185,327
Net (loss) income per share, diluted	\$ (0.54)	\$ 0.13	\$ (0.57)	\$ (2.29)

Weighted average shares of common stock outstanding, diluted	189,139	186,166	189,632	185,327
--	---------	---------	---------	---------

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data)

(Unaudited)

	For the three-month periods ended	
	March 30, 2024	April 1, 2023
Revenue	\$ 490,653	\$ 466,413
Cost of revenue, excluding depreciation and amortization	344,799	321,948
Branch and regional administrative expenses	87,914	91,708
Corporate expenses	29,842	30,935
Depreciation and amortization	2,912	4,041
Acquisition-related costs	-	70
Other operating expense	2,320	72
Operating income	22,866	17,639
Interest income	102	75
Interest expense	(39,647)	(35,958)
Other income (expense)	18,169	(12,188)
Income (loss) before income taxes	1,490	(30,432)
Income tax expense	(12,662)	(1,566)
Net loss	\$ (11,172)	\$ (31,998)
Net loss per share:		
Net loss per share, basic and diluted	\$ (0.06)	\$ (0.17)
Weighted average shares of common stock outstanding, basic and diluted	192,241	189,054

The accompanying notes are an integral part of these unaudited consolidated financial statements.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES						
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY						
(Amounts in thousands, except share data)						
(Unaudited)						
For the three-month period ended September 30, 2023						
	Common Stock		Additional Paid-in	Accumulated	Total Stockholders'	
	Shares	Amount			Deficit	Deficit
Balance, July 1, 2023	190,425,098	\$ 1,904	\$ 1,234,468	\$ (1,243,109)	\$	(6,737)
Issuance of vested restricted shares	308,055	3	(3)	-		-

Non-cash share-based compensation	-	-	3,413	-	3,413
Net loss	-	-	-	(102,389)	(102,389)
Balance, September 30, 2023	190,733,153	\$ 1,907	\$ 1,237,878	\$ (1,345,498)	\$ (105,713)

For the three-month period ended October 1, 2022

	Common Stock		Additional Paid-in	Accumulated	Total Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance, July 2, 2022	185,918,240	\$ 1,859	\$ 1,221,507	\$ (1,023,229)	\$ 200,137
Non-cash share-based compensation	-	-	3,512	-	3,512
Net income	-	-	-	24,298	24,298
Balance, October 1, 2022	185,918,240	\$ 1,859	\$ 1,225,019	\$ (998,931)	\$ 227,947

For the nine-month period ended September 30, 2023

	Common Stock		Additional Paid-in	Accumulated	Total Stockholders'
	Shares	Amount	Capital	Deficit	Deficit
Balance, December 31, 2022	188,859,165	\$ 1,888	\$ 1,228,512	\$ (1,236,710)	\$ (6,310)
Issuance of vested restricted shares	308,055	3	(3)	-	-
Employee stock purchase plan	1,565,933	16	929	-	945
Non-cash share-based compensation	-	-	8,440	-	8,440
Net loss	-	-	-	(108,788)	(108,788)
Balance, September 30, 2023	190,733,153	\$ 1,907	\$ 1,237,878	\$ (1,345,498)	\$ (105,713)

For the nine-month period ended October 1, 2022

	Common Stock		Additional Paid-in	Accumulated	Total Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance, January 1, 2022	184,732,268	\$ 1,847	\$ 1,208,645	\$ (574,676)	\$ 635,816
Employee stock purchase plan	1,185,972	12	2,266	-	2,278

Non-cash share-based compensation	-	-	14,108	-	14,108
Net loss	-	-	-	(424,255)	(424,255)
Balance, October 1, 2022	185,918,240	\$ 1,859	\$ 1,225,019	\$ (998,931)	\$ 227,947

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

(Amounts in thousands, except share data)

(Unaudited)

For the three-month period ended March 30, 2024

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount			
Balance, December 30, 2023	190,733,153	\$ 1,907	\$ 1,239,757	\$ (1,371,234)	\$ (129,570)
Employee stock purchase plan	1,010,635	10	1,339	-	1,349
Issuance of vested restricted shares	634,923	6	(6)	-	-
Non-cash share-based compensation	-	-	3,120	-	3,120
Net loss	-	-	-	(11,172)	(11,172)
Balance, March 30, 2024	192,378,711	\$ 1,923	\$ 1,244,210	\$ (1,382,406)	\$ (136,273)

For the three-month period ended April 1, 2023

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount			
Balance, December 31, 2022	188,859,165	\$ 1,888	\$ 1,228,512	\$ (1,236,710)	\$ (6,310)
Non-cash share-based compensation	-	-	2,442	-	2,442
Net loss	-	-	-	(31,998)	(31,998)
Balance, April 1, 2023	188,859,165	\$ 1,888	\$ 1,230,954	\$ (1,268,708)	\$ (35,866)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)

	For the nine-month periods ended	
	September 30, 2023	October 1, 2022
Cash Flows From Operating Activities:		
Net loss	\$ (108,788)	\$ (424,255)
Adjustments to reconcile net loss to net cash from operating activities:		
Depreciation and amortization	10,494	16,774
Amortization of deferred debt issuance costs	3,983	5,221
Amortization and impairment of operating lease right of use assets	12,490	12,722
Non-cash share-based compensation	10,143	14,108
Goodwill impairment	105,136	470,207
Loss (gain) on disposal or impairment of licenses, property and equipment, and software	2,086	1,815
Fair value adjustments on interest rate derivatives	(2,584)	(89,634)
Deferred income taxes	575	(293)
Non-cash gain on acquisition	(5,090)	-
Changes in operating assets and liabilities, net of impact of acquisitions:		
Patient accounts receivable	(14,431)	(921)
Prepaid expenses	5,247	6,825
Other current and long-term assets	(12,657)	(1,878)
Accounts payable and other accrued liabilities	(7,861)	(2,395)
Accrued payroll and employee benefits	31,752	(4,569)
Insurance reserves	229	5,884
Operating lease liabilities	(11,991)	(15,845)

Other current and long-term liabilities	6,944	(1,932)
Net cash provided by (used in) operating activities	25,677	(8,166)
Cash Flows From Investing Activities:		
Acquisitions of businesses, net of cash acquired	-	(2,027)
Proceeds from sale of businesses	-	460
Payment for interest rate cap	-	(11,725)
Purchase of certificates of need	(2,678)	-
Purchases of property and equipment, and software	(4,548)	(8,800)
Net cash used in investing activities	(7,226)	(22,092)
Cash Flows From Financing Activities:		
Proceeds from employee stock purchase plan	945	2,278
Proceeds from securitization obligation	45,000	40,000
Repayment of securitization obligation	(30,000)	(20,000)
Proceeds from revolving credit facility	20,000	15,000
Repayments on revolving credit facility	(20,000)	(15,000)
Proceeds from issuance of term loans, net of debt issuance costs	-	59,700
Principal payments on term loans	(6,900)	(6,600)
Principal payments on notes payable	(7,293)	(7,564)
Principal payments on financing lease obligations	(521)	(581)
Payment of debt issuance costs	(1,047)	(218)
Settlements with interest rate swap counterparties	10,442	(3,566)
Net cash provided by financing activities	10,626	63,449
Net change in cash and cash equivalents	29,077	33,191
Cash and cash equivalents at beginning of period	19,217	30,490
Cash and cash equivalents at end of period	\$ 48,294	\$ 63,681

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)

For the three-month periods ended

	March 30, 2024	April 1, 2023
Cash Flows From Operating Activities:		
Net loss	\$ (11,172)	\$ (31,998)

Adjustments to reconcile net loss to net cash from operating activities:

Depreciation and amortization	2,912	4,041
Amortization of deferred debt issuance costs	1,223	1,421
Amortization and impairment of operating lease right of use assets	6,233	4,236
Non-cash share-based compensation	4,081	2,442
Loss on disposal or impairment of licenses, property and equipment, and software	229	68
Fair value adjustments on interest rate derivatives	(8,276)	18,537
Deferred income taxes	614	594
Changes in operating assets and liabilities, net of impact of acquisitions:		
Patient accounts receivable	(20,986)	(20,595)
Prepaid expenses	(346)	(1,500)
Other current and long-term assets	(4,308)	(4,441)
Accounts payable and other accrued liabilities	13,065	(1,763)
Accrued payroll and employee benefits	1,793	18,316
Insurance reserves	5,679	1,960
Operating lease liabilities	(4,542)	(1,005)
Other current and long-term liabilities	1,829	17,182
Net cash (used in) provided by operating activities	(11,972)	7,495

Cash Flows From Investing Activities:

Purchase of certificates of need	-	(2,678)
Purchases of property and equipment, and software	(1,308)	(2,122)
Net cash used in investing activities	(1,308)	(4,800)

Cash Flows From Financing Activities:

Proceeds from employee stock purchase plan	1,349	-
Proceeds from securitization obligation	20,000	35,000
Repayment of securitization obligation	(10,000)	(20,000)
Proceeds from revolving credit facility	-	20,000
Repayments on revolving credit facility	-	(20,000)
Principal payments on term loans	(2,300)	(2,300)
Principal payments on notes payable	(1,383)	(3,192)
Principal payments on financing lease obligations	(65)	(206)
Settlements with interest rate swap counterparties	4,344	3,219
Net cash provided by financing activities	11,945	12,521
Net change in cash and cash equivalents	(1,335)	15,216

Cash and cash equivalents at beginning of period	43,942	19,217
Cash and cash equivalents at end of period	\$ 42,607	\$ 34,433

Supplemental Disclosures of Cash Flow Information:				
Cash paid for interest	\$ 99,291	\$ 69,572	\$ 38,491	\$ 24,196
Cash paid for income taxes, net of refunds received	\$ 766	\$ 1,410	\$ (64)	\$ (386)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

5

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. DESCRIPTION OF BUSINESS

Aveanna Healthcare Holdings Inc. (together with its consolidated subsidiaries, referred to herein as the “Company”) is headquartered in Atlanta, Georgia and has locations in 33 states with concentrations in California, Texas and Pennsylvania, providing a broad range of pediatric and adult healthcare services including nursing, hospice, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient's normal caregiver. The Company's services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying interim unaudited consolidated financial statements include the accounts of Aveanna Healthcare Holdings Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in the interim unaudited consolidated financial statements, and business combinations accounted for as purchases have been included in the interim unaudited consolidated financial statements from their respective dates of acquisition.

Basis of Presentation

The accompanying interim consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, these interim unaudited consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, these interim unaudited consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s financial position as of September 30, 2023 March 30, 2024 and the results of operations for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively. The results reported in these interim unaudited consolidated financial statements should not be regarded as indicative of results that may be expected for any other future period or the entire year, year ending December 28, 2024. These interim unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes for the fiscal year ended December 31, 2022 December 30, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 16, 2023 March 14, 2024.

Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52 or 53-week fiscal year. The interim unaudited consolidated balance sheets reflect the accounts of the Company as of September 30, 2023 March 30, 2024 and December 31, 2022 December 30, 2023. For the three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, the interim unaudited consolidated statements of operations, stockholders’ (deficit) equity, deficit, and cash flows reflect the accounts of the Company from July 2, 2023 December 31, 2023 through September 30, 2023 March 30, 2024 and July 3, 2022 through October 1, 2022, respectively. For the nine-month periods ended September 30, 2023 and October 1, 2022, the interim unaudited consolidated statements of operations, stockholders’ (deficit) equity and cash flows reflect the accounts of the Company from January 1, 2023 through September 30, 2023 and January 2, 2022 through October 1, 2022 April 1, 2023, respectively.

Use of Estimates

The Company’s accounting and reporting policies conform with U.S. GAAP. In preparing the interim unaudited consolidated financial statements, the Company is required to make estimates and assumptions that impact the amounts reported in these interim unaudited consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Recently Adopted Issued Accounting Pronouncements

In March 2020, November 2023, the FASB Financial Accounting Standards Board ("FASB") issued ASU 2020-04, 2023-07, *Reference Rate Reform Segment Reporting (Topic 848) 280*: *Facilitation Improvements to Reportable Segment Disclosures*. The standard improves reportable segment disclosure requirements for public business entities primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit (referred to as the *Effects of Reference Rate Reform* "significant expense principle"). The standard will become effective for the fiscal year 2024 annual financial statements and interim financial statements thereafter and will be applied retrospectively for all prior periods presented in the financial statements, with early adoption permitted. The Company plans to adopt the standard when it becomes effective, beginning with the Company's fiscal year 2024 annual financial statements, and is currently evaluating the impact this guidance will have on Financial Reporting, which provides optional expedients and exceptions for applying U.S. GAAP the disclosures included in the notes to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU 2021-01, *Reference Rate Reform (Topic consolidated financial statements)*.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

848): Scope, which clarifies the scope and application of certain optional expedients and exceptions regarding the original guidance. In December 2022, 2023, the FASB issued ASU 2022-06, 2023-09, *Reference Rate Reform Income Taxes (Topic 848) 740*: *Deferral of the Sunset Date of Topic 848 Improvements to Income Tax Disclosures*, which delays the effective date of the guidance issued in ASU 2020-04 to December 31, 2024. The U.S. Dollar LIBOR panel ceased following June 30, 2023, standard enhances income tax disclosure requirements for all entities by requiring specified categories and greater disaggregation within the rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. The standard will be effective for the fiscal year 2025 annual financial statements with early adoption permitted. The Company plans to adopt the standard when it becomes effective beginning with the Company's fiscal year 2025 annual financial statements, and the Company adopted expects the guidance in ASU 2020-04 for adoption of the

second quarter standard will impact certain of fiscal year 2023 on a prospective basis, which did not have a material impact on the Company's financial position, results of operations, and its income tax disclosures.

3. REVENUE

The Company evaluates the nature, amount, timing and uncertainty of revenue and cash flows using the five-step process. The Company uses a portfolio approach to group contracts with similar characteristics and analyze historical cash collection trends.

Revenue is primarily derived from (i) pediatric healthcare services provided to patients, including private duty nursing and therapy services; (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and time; therefore, each service provided is its own stand-alone contract. Incremental costs of obtaining a contract are expensed as incurred due to the short-term nature of the contracts.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. For patient revenue, the performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For product revenue, the performance obligation is satisfied at the point in time of delivery of the product to the patient. The Company recognizes patient revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payers are billed within several days of the service being performed, and payments are due based on contract terms.

The Company's lines of business are generally classified into the following categories: private duty services; home health and hospice; and medical solutions.

Private Duty Services ("PDS"). The PDS business includes a broad range of pediatric and adult healthcare services, including private duty skilled nursing, non-clinical services, which include employer of record support services and personal care services, pediatric therapy services, rehabilitation services, and nursing services in schools and pediatric day healthcare centers.

Home Health & Hospice ("HHH"). The HHH business provides home health, hospice, and personal care services to predominately elderly patients.

Medical Solutions ("MS"). The MS business includes the delivery of enteral nutrition and other products to patients.

For the PDS, HHH, and MS businesses, the Company receives payments from the following sources for services rendered: (i) state governments under their respective Medicaid programs ("Medicaid"); (ii) Managed Care providers of state government Medicaid programs ("Medicaid MCO"); (iii) commercial insurers; (iv) other government programs

including Medicare, Tricare and ChampVA (“Medicare”); and (v) individual patients. As the period between the time of service and time of payment is typically one year or less, the Company did not adjust for the effects of a significant financing component.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments and discounts provided to third-party payers and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements and historical experience. Implicit price concessions are based on historical collection experience. As of September 30, 2023 and December 31, 2022, estimated explicit and implicit price concessions of \$57.2 million and \$52.6 million, respectively, were recorded as reductions to patient accounts receivable balances to arrive at the estimated collectible revenue and patient accounts receivable. Most contracts contain variable consideration, however, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payers and by implicit price concessions which are estimated based on historical collection experience. Management estimates the transaction price on a payer-specific basis given its interpretation of the applicable regulations or contract terms. Updated regulations and contract negotiations occur frequently, necessitating regular review and assessment by management. There were no material revenue adjustments recognized from performance obligations satisfied or partially satisfied in previous periods for the three-month periods ended March 30, 2024 and April 1, 2023, respectively.

7

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

As of March 30, 2024 and December 30, 2023, estimated contractual adjustments and implicit price concessions of \$68.5 million and \$62.6 million, respectively, were recorded as reductions to patient accounts receivable balances to arrive at the estimated collectible revenue and patient accounts receivable. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense which is included as a component of operating expenses in the consolidated statements of operations. The Company did not record any bad debt expense for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022, respectively.

The Company derives a significant portion of its revenue from Medicaid, Medicaid MCO, Medicare and other payers that receive discounts from established billing rates. The regulations and various managed care contracts under which these discounts must be

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

estimated are complex and subject to interpretation. Management estimates the transaction price on a payer-specific basis given its interpretation of the applicable regulations or contract terms. Updated regulations and contract negotiations occur frequently, necessitating regular review and assessment of the estimation process by management; however, there were no material revenue adjustments recognized from performance obligations satisfied or partially satisfied in previous periods for the three and nine-month periods ended September 30, 2023 and October 1, 2022 April 1, 2023, respectively.

The following table presents revenue by payer type as a percentage of total revenue for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively:

	For the three-month periods ended		For the nine-month periods ended		For the three-month periods ended	
	September 30, 2023	October 1, 2022	September 30, 2023	October 1, 2022	March 30, 2024	April 1, 2023
Medicaid MC		50.		51.		
O	56.8 %	9 %	55.2 %	6 %	56.0 %	54.6 %
Medicaid		21.		21.		
	22.0 %	6 %	22.0 %	8 %	22.3 %	22.5 %
Commercial	9.0 %	8.4 %	10.0 %	9.4 %	10.9 %	10.2 %
Medicare		19.		17.		
e	12.0 %	0 %	12.7 %	1 %	10.7 %	12.6 %

Self-pay	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
To						
tal						
re						
ve						
n						
u	100.	100	100.	100		
e	0%	.0%	0%	.0%	100.0%	100.0%

4. GOODWILL

The following table summarizes changes in goodwill by segment at December 31, 2022 through the nine-month period ended September 30, 2023 (amounts in thousands):

	PDS	HHH	MS	Total
Balance at December 31, 2022, net ⁽¹⁾	897,728	151,324	110,636	1,159,688
Impairments	-	(105,136)	-	(105,136)
Balance at September 30, 2023, net ⁽²⁾	897,728	46,188	110,636	1,054,552

⁽¹⁾ Goodwill balance is net of accumulated impairment losses of \$608.0 million for PDS, \$119.8 million for MS, and \$382.3 million for HHH.

⁽²⁾ Goodwill balance is net of accumulated impairment losses of \$608.0 million for PDS, \$119.8 million for MS, and \$487.4 million for HHH.

A test of goodwill impairment is required at least annually or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. As a result of previously anticipated volume not being actualized to forecasted levels in the reporting unit within our HHH segment, the Company revised its forward-looking estimates and performed an interim impairment assessment as of September 30, 2023. Based on that assessment, the Company determined that the reporting unit within our HHH segment exceeded its respective fair values and the Company accordingly recorded an aggregate goodwill impairment charge of \$105.1 million during the three-month period ended September 30, 2023.

For its interim goodwill impairment test, the Company engaged a third-party valuation firm to assist in calculating the fair value of each of the Company's reporting units, which is derived using an income approach or a combination of both income and market approaches. The income approach utilizes projected operating results and cash flows and includes significant assumptions, such as revenue growth rates, projected EBITDA margins, and discount rates. The market approach compares its reporting units' earnings and revenue multiples to those of comparable public companies. Estimates of fair value may differ from actual results due to, among other things, economic conditions, changes to business models or changes in operating performance. These factors increase the risk of differences

between projected and actual performance that could impact future estimates of fair value of all reporting units. Significant differences between these estimates and actual future performance could result in additional impairment in future fiscal periods.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

5. LONG-TERM OBLIGATIONS

Long-term obligations consisted of the following as of September 30, 2023, March 30, 2024 and December 31, 2022, December 30, 2023, respectively (dollar amounts in thousands):

Instrument	Stated Maturity Date	Contractual Interest Rate	Interest Rate as of		
			September 30, 2023	September 30, 2023	December 31, 2022
2021 Extended Term Loan ⁽¹⁾	07/2028	S + 3.75%	9.27%	\$ 902,050	\$ 908,950
Second Lien Term Loan ⁽¹⁾	12/2029	S + 7.00%	12.52%	415,000	415,000
Revolving Credit Facility ⁽²⁾	04/2026	S + 3.75%	9.27%	-	-
Total principal amount of long-term obligations				1,317,050	1,323,950
Less: unamortized debt issuance costs				(30,268)	(33,668)
Total amount of long-term obligations, net of unamortized debt issuance costs				1,286,782	1,290,282
Less: current portion of long-term obligations				(9,200)	(9,200)
Total amount of long-term obligations, net of unamortized debt issuance costs, less current portion				\$ 1,277,582	\$ 1,281,082

⁽¹⁾ S = Greater of 0.50% or one-month SOFR, plus a CSA

⁽²⁾ S = One-month SOFR, plus a CSA

On March 23, 2023, the Company amended the agreement governing the Revolving Credit Facility to increase the sublimit for letters of credit to \$40.0 million from \$30.0 million. The other terms of the Revolving Credit Facility remained unchanged.

On June 30, 2023, the Company entered into the Ninth Amendment to the 2021 Extended Term Loan and the First Amendment to the Second Lien Term Loan. The Company entered into these amendments in order to remove and

replace the LIBOR-based interest rate benchmark provisions with interest rate benchmark provisions based on a term secured overnight financing rate ("SOFR").

Instrument	Stated Maturity Date	Interest Rate Contractual Interest Rate	Interest Rate		
			as of March 30, 2024	March 30, 2024	December 30, 2023
2021 Extended Term Loan ⁽¹⁾	07/2028	S + 3.75%	9.19%	\$ 897,450	\$ 899,750
Second Lien Term Loan ⁽¹⁾	12/2029	S + 7.00%	12.49%	415,000	415,000
Revolving Credit Facility ⁽¹⁾	04/2026	S + 3.75%	9.19%	-	-
Total principal amount of long-term obligations				1,312,450	1,314,750
Less: unamortized debt issuance costs				(28,123)	(29,209)
Total amount of long-term obligations, net of unamortized debt issuance costs				1,284,327	1,285,541
Less: current portion of long-term obligations				(9,200)	(9,200)
Total amount of long-term obligations, net of unamortized debt issuance costs, less current portion				\$ 1,275,127	\$ 1,276,341

⁽¹⁾ S = Greater of 0.50% or one-month SOFR, plus a credit spread adjustment

The 2021 Extended Term Loan bears interest, at the Company's election, at a variable interest rate based on either SOFR (subject to a minimum of 0.50%), or an alternative base rate ABR (subject to a minimum of 2.00%) for the interest period relevant to such borrowing, plus a credit spread adjustment ("CSA") of 0.10% and an applicable margin of 3.75% for loans accruing interest based on SOFR, and an applicable margin of 2.75% for loans accruing interest based on ABR. The Revolving Credit Facility bears interest, at the Company's election, at a variable interest rate based on either SOFR or ABR (subject to a minimum of 2.00%) for the interest period relevant to such borrowing, plus a CSA of 0.10% and an applicable margin of 3.75% for loans accruing interest based on SOFR, and an applicable margin of 2.75% for loans accruing interest based on ABR. As of September 30, 2023 March 30, 2024, the principal amount of the 2021 Extended Term Loan and borrowings under the Revolving Credit Facility accrued interest at a rate of 9.27 9.19%.

The Second Lien Term Loan bears interest at a rate per annum equal to, at the Company's option, election, either (1) an applicable margin (equal to 6.00%) plus a base rate determined by reference to the highest of (a) 0.50% per annum plus the Federal Funds Effective Rate, (b) the Prime Rate and (c) the SOFR rate for an interest period of one month plus a CSA depending on the interest period plus 1.00%; or (2) an applicable margin (equal to 7.00%) plus SOFR and a CSA depending on the interest period; provided that such rate is not lower than a floor of 0.50%. As of

September 30, 2023 March 30, 2024, the principal amount of the Second Lien Term Loan accrued interest at a rate of 12.52 12.49%.

8

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Debt issuance costs related to the term loans are recorded as a direct deduction from the carrying amount of the debt. The balance for debt issuance costs related to the term loans as of September 30, 2023 March 30, 2024 and December 31, 2022 December 30, 2023 was \$30.3 28.1 million and \$33.3 million, respectively. Debt issuance costs related to the Revolving Credit Facility are recorded within other long-term assets. The balance for debt issuance costs related to the Revolving Credit Facility as of September 30, 2023 and December 31, 2022 was \$0.0 million and \$0.4 29.2 million, respectively. The Company recognized interest expense related to the amortization of debt issuance costs of \$1.1 million and \$3.6 1.4 million during the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$1.6 million and \$4.9 million during the three and nine-month periods and October 1, 2022 April 1, 2023, respectively.

Issued letters of credit as of September 30, 2023 March 30, 2024 and December 31, 2022 December 30, 2023 were \$32.0 31.8 million and \$19.7 31.9 million, respectively. There were no swingline loans outstanding as of September 30, 2023 March 30, 2024 or December 31, 2022 December 30, 2023. Borrowing capacity under the Company's

9

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Revolving Credit Facility was approximately \$168.0 168.2 million as of September 30, 2023 March 30, 2024 and \$180.3 168.1 million as of December 31, 2022 December 30, 2023. Available borrowing capacity under the Revolving Credit Facility is subject to a maintenance leverage covenant that becomes effective if more than 30% of the total commitment is utilized.

The fair value of the Company's long-term obligations was estimated using market-observable inputs from the Company's comparable peers with public debt, including quoted prices in active markets, which are considered Level

2 inputs. The aggregate fair value of the Company's long-term obligations was \$1,079.3 1,212.0 million at September 30, 2023 March 30, 2024.

The Company was in compliance with all financial covenants and restrictions under the foregoing instruments at September 30, 2023 March 30, 2024.

6.5. SECURITIZATION FACILITY

On November 12, 2021, the Company (through a wholly owned special purpose entity, Aveanna SPV I, LLC) (the "special purpose entity") and a lending institution entered into a Receivables Financing Agreement, (as which, as amended, the "Securitization Facility") with has a termination date of November 12, 2024. On July 31, 2023, the Company entered into an amendment to the Securitization Facility to extend its maturity date to of July 31, 2026 (as amended, the "Securitization Facility"). The maximum amount available under the Securitization Facility is \$175.0 million, subject to certain borrowing base requirements. The Company incurred debt issuance costs of \$2.4 million in connection with the Securitization Facility, which were capitalized and included in other long-term assets. The Company recognized interest expense related to the amortization of debt issuance costs of \$0.1 million and \$0.4 0.1 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$0.1 million and \$0.3 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively.

Pursuant to two separate sale agreements, each of which is among Aveanna Healthcare, LLC, as initial servicer, certain of the Company's subsidiaries and the special purpose entity, the subsidiaries sold substantially all of their existing and future accounts receivable balances to the special purpose entity. The special purpose entity uses the accounts receivable balances to collateralize loans made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty.

The outstanding balance under the Securitization Facility was \$155.0 165.0 million and \$140.0 155.0 million at September 30, 2023 March 30, 2024 and December 31, 2022 December 30, 2023, respectively. The balance accrues interest at a rate equal to the SOFR rate, plus a CSA, plus an applicable margin. The interest rate under the Securitization Facility was 8.91 8.93% at September 30, 2023 March 30, 2024.

The Securitization Facility is accounted for as a collateralized financing activity, rather than a sale of assets, and assets; therefore: (i) accounts receivable balances pledged as collateral are presented as assets and the borrowings are presented as liabilities in the interim unaudited consolidated balance sheets; (ii) the consolidated statements of operations reflect the interest expense associated with the collateralized borrowings; and (iii) receipts from customers related to the underlying accounts receivable are reflected as operating cash flows and borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows. The Securitization Facility is included within current liabilities on the interim unaudited

consolidated balance sheets as it is collateralized by current patient accounts receivable and not because payments are due within one year of the balance sheet date.

7.6. FAIR VALUE MEASUREMENTS

The carrying amounts of cash and cash equivalents, patient accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair values due to the short-term maturities of the instruments.

The Company's other assets measured at fair value were as follows (amounts in thousands):

109

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Fair Value Measurements at September 30, 2023				
	Level 1	Level 2	Level 3	Total
Assets:				
Interest rate cap agreements	\$ -	\$ 49,204	\$ -	\$ 49,204
Interest rate swap agreements	-	35,130	-	35,130
Total derivative assets	\$ -	\$ 84,334	\$ -	\$ 84,334
Fair Value Measurements at December 31, 2022				
	Level 1	Level 2	Level 3	Total
Assets:				
Interest rate cap agreements	\$ -	\$ 47,459	\$ -	\$ 47,459
Interest rate swap agreements	-	34,291	-	34,291
Total derivative assets	\$ -	\$ 81,750	\$ -	\$ 81,750
Fair Value Measurements at March 30, 2024				
	Level 1	Level 2	Level 3	Total
Assets:				

Interest rate cap agreements	\$	-	\$	35,293	\$	-	\$	35,293
Interest rate swap agreements		-		26,460		-		26,460
Total derivative assets	\$	-	\$	61,753	\$	-	\$	61,753

Fair Value Measurements at December 30, 2023

	Level 1	Level 2	Level 3	Total
Assets:				
Interest rate cap agreements	\$	-	\$	30,455
Interest rate swap agreements		-		23,022
Total derivative assets	\$	-	\$	53,477

The fair values of the interest rate swap and cap agreements are based on the estimated net proceeds or costs to settle the transactions as of the respective balance sheet dates. The valuations are based on commercially reasonable industry and market practices for valuing similar financial instruments. See Note 87 – *Derivative Financial Instruments* for further details on the Company's interest rate swap and cap agreements.

For the interim goodwill impairment test, the Company performed a Step 1 analysis that used an expected present value of future cash flows (income approach) or a combination of the income approach and comparable public companies (market approach) to determine the fair value of the reporting unit. These approaches use primarily unobservable inputs, including revenue growth rates, projected EBITDA margins, and discount rates, which are considered Level 3 fair value measurements. The fair value analysis takes into account recent and expected operating performance.

8.7. DERIVATIVE FINANCIAL INSTRUMENTS

The Company's earnings and cash flows are subject to fluctuations due to changes in interest rates, and the Company seeks to mitigate a portion of this risk by entering into derivative contracts. The derivatives the Company currently uses are interest rate swaps and interest rate caps. The Company recognizes derivatives as either assets or liabilities at fair value on the interim unaudited consolidated balance sheets and does not designate the derivatives as hedging instruments. Changes in the fair value of derivatives are therefore recorded in earnings throughout the term of the respective derivatives.

The Company currently has two interest rate swap agreements intended to limit its exposure to interest rate risk on its variable rate debt. These swaps expire on June 30, 2026. Prior to the quarter ended July 1, 2023, the interest rate swap agreements paid a fixed rate of 2.08% and received the one-month LIBOR rate, subject to a 0.50% floor. During the quarter ended July 1, 2023, the Company amended its interest rate swap agreements to change the benchmark rate under the agreements from LIBOR to SOFR. As of Since July 1, 2023, the interest rate swap agreements have paid a fixed rate of 2.03% and received the one-month SOFR rate, subject to a 0.50% floor. The aggregate notional amount of the interest rate swaps remained unchanged at \$520.0 million at September 30, 2023 March 30, 2024 and

December 31, 2022 December 30, 2023, respectively. The fair value of the interest rate swaps was \$35.1 26.5 million at September 30, 2023 March 30, 2024 and \$34.3 23.0 million at December 31, 2022 December 30, 2023 and is included in other long-term assets in the interim unaudited consolidated balance sheets. The Company does not apply hedge accounting to these agreements and records all mark-to-market adjustments directly to other income in the consolidated statements of operations, which are included within cash flows from operating activities in the consolidated statements of cash flows. The net settlements incurred with swap counterparties under the swap agreements are recognized through cash flows from financing activities in the consolidated statements of cash flows due to an other-than-insignificant financing element on the interest rate swaps.

On February 9, 2022, the The Company entered into has interest rate cap agreements for with an aggregate notional amount of \$880.0 million and a cap rate of 3.00%. The premium paid for the interest rate cap agreements was \$11.7 million. The cap agreements have an expiration date of February 28, 2027. Prior to the quarter ended July 1, 2023, the cap agreements provided that the counterparty will would pay the Company the amount by which LIBOR exceeded 3.00% in a given measurement period. During the quarter ended July 1, 2023, the Company amended its interest rate cap agreements to provide that the counterparty will would pay the Company the amount by which SOFR exceeds 2.96%. The fair value of the interest rate cap agreements was \$49.2 35.3 million at September 30, 2023 March 30, 2024 and \$47.5 30.5 million at December 31, 2022 December 30, 2023 and is included in other long-term assets on the interim unaudited consolidated balance sheets. The Company does not apply hedge accounting to interest rate cap agreements and records all mark-to-market adjustments directly to other income in the consolidated statements of operations, which are included within cash flows from operating activities in the consolidated statement of cash flows.

11 10

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

operating activities in the consolidated statement of cash flows. Proceeds from settlements with cap counterparties are included within cash flows from operating activities in the consolidated statement of cash flows. The premium payments on the interest rate caps were recognized through cash flows from investing activities.

The following losses and gains from these derivatives not designated as hedging instruments were recognized in the Company's consolidated statements of operations for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively (amounts in thousands):

	Statement of Operations	For the three-month periods ended		Statement of Operations	For the three- month periods ended	
		September 30, 2023	October 1, 2022		March 30, 2024	April 1, 2023
Classification				Classification		
Interest rate cap agreements	Other income	\$ 1,366	\$ 24,339	Other income (expense)	\$ 4,838	\$ (11,036)
Interest rate swap agreements	Other income	\$ 2,956	\$ 20,505	Other income (expense)	\$ 3,438	\$ (7,501)
	Statement of Operations	For the nine-month periods ended				
		September 30, 2023	October 1, 2022			
Classification						
Interest rate cap agreements	Other (expense) income	\$ 839	\$ 38,003			
Interest rate swap agreements	Other (expense) income	\$ 1,745	\$ 51,631			

The Company does not utilize financial instruments for trading or other speculative purposes.

9.8. INCOME TAXES

The Company's provision for income taxes is recorded on an interim basis based upon the Company's estimate of the annual effective income tax rate for the full year applied to "ordinary" income or loss, adjusted each quarter for discrete items.

The Company recorded an income tax expense of \$0.612.7 million and \$1.41.6 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and an income tax benefit of \$2.7 million and \$0.4 million for the three and nine-month periods and October 1, 2022 April 1, 2023, respectively. The Company's effective tax rate was negative 0.6849.8% and negative 1.35.1% for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and negative 12.3% and negative 0.1% for the three and nine-month periods and October 1, 2022 April 1, 2023, respectively. The effective tax rates for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 differed from the statutory rate of 21% primarily due to increased current federal and state taxes resulting from certain

non-deductible expenses, most notably interest expense, and the changes in the valuation allowance recorded against certain deferred tax assets, and separate state and local income taxes on taxable subsidiaries. assets.

For the nine-month three-month period ended September 30, 2023 March 30, 2024, there were no material changes to the Company recognized a benefit of approximately \$1.5 million from the reversal of acquired Company's uncertain tax positions. There has been no change to the Company's Company's policy that recognizes potential interest and penalties related to uncertain tax positions in income tax expense in the accompanying consolidated statements of operations.

10.9. SHARE-BASED COMPENSATION

Pre-IPO Options and Management Restricted Units

The Company recorded compensation expense, net of forfeitures, of \$1.50.8 million and \$2.30.5 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$1.7 million and \$9.1 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively, which is included in corporate and branch and regional administrative expenses in the accompanying consolidated statements of operations. Unrecognized compensation expense as of September 30, 2023 March 30, 2024 associated with these outstanding awards was \$58.6.8 million.

Director Restricted Stock Units

In February 2023, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") approved grants of 634,923 331,950 restricted stock units, with a grant date per share fair value of \$1.262.41, to certain independent Directors ("Director RSUs"). Director RSUs vest over a one-year period. The Company recorded compensation expense of \$0.30.2 million and \$0.90.3 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$0.1 million and \$0.4 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively, which is included in corporate expenses in the accompanying consolidated statements of operations. Unrecognized compensation expense as of September 30, 2023 March 30, 2024 associated with outstanding director restricted stock units was \$0.30.7 million.

12

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Employee Stock Purchase Plan

During the three-month periods ended September 30, 2023 and October 1, 2022, no purchase events related to the Employee Stock Purchase Plan occurred. Participants purchased a total of 1,565,933 shares of common stock at a price of \$0.60 per share during the nine-month period ended September 30, 2023. Participants purchased a total of

1,185,972 shares of common stock at a price of \$1.92 per share during the nine-month period ended October 1, 2022. The Company recorded compensation expense of \$0.3 million and \$0.8 million for the three and nine-month periods ended September 30, 2023, respectively, and \$0.5 million and \$1.7 million for the three and nine-month periods ended October 1, 2022, respectively, which is included in corporate expenses, branch and regional administrative expenses and cost of revenue, excluding depreciation and amortization in the accompanying consolidated statements of operations.

Long-Term Incentive Plan ("LTIP")

During the three-month period ended April 1, 2023 March 30, 2024, the Compensation Committee of the Company's Board of Directors approved grants of restricted stock units ("RSUs") and performance stock units ("PSUs") under the Company's 2021 Omnibus Stock Incentive Plan.

The RSUs are subject to a three-year service-based cliff vesting schedule commencing on the date of grant. Compensation cost for the RSUs is measured based on the grant date fair value of each share and the number of shares granted and is recognized over the applicable vesting period on a straight-line basis. During the three-month period ended April 1, 2023 March 30, 2024, the Company granted 4,073,186 2,873,968 RSUs with a grant date per share fair value of \$1.26 2.41. The PSUs contain a performance criteria based on an adjusted EBITDA target over a three-year performance period. The PSUs are also subject to a three-year service-based cliff vesting schedule commencing on the date of grant. The PSUs have a service and a performance condition and compensation cost is

11

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

initially measured based on the grant date fair value of each share. Cumulative compensation cost is subsequently adjusted at the end of each reporting period to reflect the current estimation of achieving the performance condition. During the three-month period ended April 1, 2023 March 30, 2024, the Company granted 4,073,108 2,873,881 PSUs with a weighted average grant date per share fair value of \$1.26 2.41.

The Company recorded Total compensation expense, net of forfeitures, of \$ for all outstanding awards under the LTIP described above was \$11.2.7 million and \$4.4 1.4 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$1.1 million and \$2.9 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively, which is included in corporate and branch and regional administrative expenses in the accompanying consolidated statements of operations. Total unrecognized compensation expense for all awards under the LTIP was \$18.9 million as of March 30, 2024.

Senior Management Retention Plan ("SMRP")

In the second quarter of 2023, the Compensation Committee approved SMRP awards to certain members of management to be paid in the form of RSUs under the 2021 Omnibus Stock Incentive Plan. The awards were granted based on a fixed dollar value for each member of senior management included in the plan. The Company recorded compensation expense, net of forfeitures, of \$1.0 million during the three-month period ended March 30, 2024, which is included in corporate expenses and branch and regional administrative expenses in the accompanying consolidated statements of operations. Unrecognized compensation expense as of September 30, 2023 March 30, 2024 associated with outstanding LTIP the remaining SMRP awards was \$12.3 11.2 million.

Employee Stock Purchase Plan

During the three-month period ended March 30, 2024, participants purchased a total of 1,010,635 shares of common stock at a price of \$1.33 per share. The Company recorded compensation expense of \$0.4 million and \$0.2 million for the three-month periods ended March 30, 2024 and April 1, 2023, respectively, which is included in corporate expenses, branch and regional administrative expenses and cost of revenue, excluding depreciation and amortization in the accompanying consolidated statements of operations.

11.10. COMMITMENTS AND CONTINGENCIES

Insurance Reserves

As is typical in the healthcare industry, the Company is subject to claims that its services have resulted in patient injury or other adverse effects.

The accrued professional malpractice insurance reserves included in the interim unaudited consolidated balance sheets include estimates of the ultimate costs, including third-party legal defense costs, in the event the Company was unable to receive funds from claims made under commercial insurance policies, for claims that have been reported but not paid and claims that have been incurred but not reported at the balance sheet dates. Although substantially all reported claims are paid directly by the Company's commercial insurance carriers (after the Company satisfies the applicable policy deductible and/or retention), the Company is ultimately responsible for payment of these claims in the event its insurance carriers become insolvent or otherwise do not honor the contractual obligations under the malpractice policies. The Company is required under U.S. GAAP to recognize these estimated liabilities in its consolidated financial statements on a gross basis; with a corresponding receivable from the insurance carriers reflecting the contractual indemnity provided by the carriers under the related malpractice policies.

Through September 30, 2023 Since October 1, 2023, the Company has maintained primary commercial insurance coverage on a claims-made basis for professional malpractice claims with a \$1.5 2.0 million per claim deductible and \$5.0 4.5 million per claim and annual aggregate limits. Prior to October 1, 2022 October 1, 2023, the Company maintained primary commercial insurance coverage on a claims made basis for professional malpractice claims with varying deductibles by policy year from \$0.5 million to \$1.0 1.5 million on a per claim basis and \$5.5 5.0 million to \$6.0

million per claim and annual aggregate limits. Moreover, the Company maintains excess insurance coverage for professional malpractice claims. claims to cover any claims over the aggregate limits. In addition, the Company maintains workers' compensation insurance with a \$0.5 million per

13

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

claim deductible and statutory limits. The Company reimburses insurance carriers for deductible losses under these policies. The Company's insurance carriers require collateral to secure the Company's obligation to reimburse insurance carriers for these deductible payments. Collateral as of September 30, 2023 March 30, 2024 was comprised of \$22.9 22.7 million of issued letters of credit and \$1.9 0.7 million in cash collateral. Collateral as of December 31, 2022 December 30, 2023 was comprised of \$19.7 22.7 million of issued letters of credit and \$1.9 0.7 million in cash collateral, and \$ collateral.

2.9 12

million in surety bonds.

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

As of September 30, 2023 March 30, 2024, insurance reserves totaling \$97.1 102.9 million were included on the interim unaudited consolidated balance sheets, representing \$45.1 42.0 million and \$52.0 60.9 million of reserves for professional malpractice claims and workers' compensation claims, respectively. At December 31, 2022 December 30, 2023, insurance reserves totaling \$90.3 91.8 million were included on the consolidated balance sheets, representing \$41.8 39.4 million and \$48.5 52.4 million of reserves for professional malpractice claims and workers' compensation claims, respectively.

Litigation and Other Current Liabilities

On December 24, 2018, Aveanna Healthcare LLC, an indirect wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the "Agreement") to acquire a pediatric home health company (the "Pediatric Home Health Seller"). The agreement contained a provision whereby a \$75.0 million transaction termination fee (the "Break-up Fee") could be payable to the Pediatric Home Health Seller under certain circumstances. On December 20, 2019, Aveanna Healthcare LLC terminated the Agreement, and the Pediatric Home Health Seller demanded

payment of the Break-up Fee. The Company believes the Agreement was terminated for cause, no payment of the Break-up Fee is due to the Pediatric Home Health Seller and all potential claims and counterclaims related to the termination of the Agreement and payment of the Break-up Fee by either party are time barred.

On August 6, 2020, the Company sued Epic/Freedom, LLC ("Seller"), Webster Capital Corporation, and Webster Equity Partners (collectively, the "Defendants") in the Delaware Superior Court. The Company asserted that the Defendants made fraudulent representations and warranties in connection with the Seller acquisition. Company's acquisition of Epic Health Services Inc. The Company sought damages ranging from \$24.0 million to \$50.0 million. The Company also requested a declaratory judgment holding that the Defendants waived any claim to the Company's continued possession of \$7.1 million in escrow funds (the "Escrow Funds") that were delivered to the Company in January 2018 by the Seller acquisition escrow agent. In response, the Defendants asserted four counterclaims: (1) specific performance of an alleged right to control a tax audit; (2) advancement of litigation fees and expenses for certain individual Defendants; (3) a declaratory judgment; and (4) breach of contract claim concerning the Escrow Funds. The Company subsequently reached an agreement with the Defendants, which (1) allowed the Defendants to take a principal role in the applicable tax audit, though the Company will continue to communicate with the Internal Revenue Service and retain the ability to make strategic decisions with respect to the audit and (2) dismissed claims against certain individual Defendants mooted Defendants' claims for advancement of litigation fees and expenses. On March 10, 2023, the parties entered into a confidential settlement agreement releasing all claims related to this matter and ending all related litigation. The settlement did not have a material impact on the consolidated results of operations. On April 4, 2023, as part of the settlement, the Company funded \$6.8 million to an escrow account for the purpose of settling certain tax audits with the IRS, which are currently under appeal have now been effectively settled with the IRS. To the extent that any additional amounts due to the IRS exceed the escrowed funds, we as the taxpayer, will be required to fund such amounts, but we have contractual rights to reimbursement from the Defendants.

On November 23, 2022, a judgment in the amount of \$19.8 million was rendered against the Company related to a civil litigation matter in Texas. In March 2023, the plaintiffs attempted to enforce the judgment by seeking a writ of garnishment, and \$18.4 million was garnished from the Company's cash accounts. The Company promptly obtained and recorded an \$18.4 million cash collateralized appellate bond with the state trial court, and such court dissolved the writ of garnishment and ordered the return of the previously garnished funds. All previously garnished funds have been returned to the Company. In July 2023, the Company and the plaintiffs reached a confidential settlement agreement wherein the plaintiffs have agreed to release all claims and extinguish the aforementioned judgment in exchange for a settlement payment. The corresponding appeal of the judgment has been discontinued upon finalization of the settlement and the Company has secured the return of the underlying collateral for the aforementioned appellate bond. The settlement did not have a material impact on the consolidated results of operations.

On January 18, 2023, an arbitration award in the amount of \$7.9 million was rendered against the Company related to a claim under the Company's Texas non-subscriber benefit plan. After the trial court entered a judgment to

enforce the arbitration award, the Company promptly obtained a \$9.1 million collateralized appellate bond and intends to avail itself of all appellate options. The ultimate resolution of these litigated matters is not expected to have a material impact on the consolidated financial statements.

14

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The Company is currently a party to various routine litigation incidental to the business. While management currently believes that the ultimate outcome of such proceedings, individually and in the aggregate, will not have a material adverse effect on the Company's financial position or overall trends in results of operations, litigation is subject to inherent uncertainties. Management has established provisions within other current liabilities in the **interim unaudited accompanying** consolidated balance sheets, which in the opinion of management represents the best estimate of exposure and adequately provides for such losses that may occur from asserted claims related to the provision of professional services and which may not be covered by the Company's insurance policies. Management believes that any additional unfavorable provisions would not be material to the Company's results of operations or financial position; however, if an unfavorable ruling on any asserted or unasserted claim were to occur, there exists the possibility of a material adverse impact on the Company's net earnings or financial position. The estimate of the potential impact from legal proceedings on the Company's financial position or overall results of operations could change in the future.

Healthcare Regulatory Matters

Starting on October 30, 2019 the Company has received grand jury subpoenas issued by the U.S. Department of Justice, Antitrust Division (the "Antitrust Division"), requiring the production of documents and information pertaining to nurse wages, reimbursement rates, and hiring activities in a few of its local markets. The Company is fully cooperating with the Antitrust

13

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Division with respect to this investigation, and management believes that a loss event is not probable and that this matter will not materially impact the Company's business, results of operations or financial condition. However, based on the information currently available to the Company, management cannot predict the timing or outcome of this investigation or predict the possible loss or range of loss, if any, associated with the resolution of this matter.

On July 19, 2023, the Company received a Civil Investigation Demand issued by the U.S. Department of Justice, United States Attorney's Office, Middle District of Alabama (the "AUSA"), requiring the production of documents and information pertaining to Comfort Care Hospice, LLC, an indirect wholly owned subsidiary of the Company, regarding **allegations issues** of (1) improper submission of claims to Medicare and other federal healthcare programs for service to patients who were ineligible or not properly certified for said healthcare services and (2) improper remuneration to medical directors and skilled nursing facilities for patient referrals in violation of certain federal regulations. The Company is fully cooperating with the AUSA with respect to this investigation, and management believes that a loss event is not probable and that this matter will not materially impact the Company's business, results of operations or financial condition. However, based on the information currently available to the Company, management cannot predict the timing or outcome of this investigation or predict the possible loss or range of loss, if any, associated with the resolution of this matter.

Laws and regulations governing the government payer programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action. From time to time, governmental regulatory agencies conduct inquiries and audits of the Company's practices. It is the Company's practice to cooperate fully with such inquiries. In addition to laws and regulations governing the Medicaid, Medicaid Managed Care, and Tricare programs, there are a number of federal and state laws and regulations governing matters such as the corporate practice of medicine, fee splitting arrangements, anti-kickback statutes, physician self-referral laws, false or fraudulent claims filing and patient privacy requirements. Failure to comply with any such laws or regulations could have an adverse impact on the Company's operations and financial results. The Company believes that it is in material compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of wrongdoing.

12. **11.** RELATED PARTY TRANSACTIONS

As of **September 30, 2023** **March 30, 2024**, one of the Company's majority stockholders owned 5.1% of the Company's 2021 Extended Term Loan.

13. **12.** SEGMENT INFORMATION

The Company's operating segments have been identified based upon how management has organized the business by services provided to customers and how the chief operating decision maker ("CODM") manages the business and allocates resources. The Company has three operating segments and three reportable segments, Private Duty Services, Home Health & Hospice, and Medical Solutions. The PDS segment predominantly includes private duty

skilled nursing services, non-clinical and personal care services, and pediatric therapy services. The HHH segment provides home health and hospice services to predominately elderly patients. Through the MS segment, the Company provides enteral nutrition and other products to adults and children, delivered on a periodic or as-needed basis.

15

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The CODM evaluates performance using gross margin (and gross margin percentage). Gross margin includes revenue less all costs of revenue, excluding depreciation and amortization, but excludes branch and regional administrative expenses, corporate expenses and other non-field expenses. The CODM does not evaluate a measure of assets when assessing performance.

Results shown for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 are not necessarily those which would be achieved if each segment was an unaffiliated business enterprise. There are no intersegment transactions.

The following tables summarize the Company's segment information for the three and nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively (amounts in thousands):

	For the three-month period ended September 30, 2023			
	PDS	HHH	MS	Total
Revenue	\$ 384,750	\$ 52,989	\$ 40,271	\$ 478,010
Cost of revenue, excluding depreciation and amortization	280,288	27,597	22,861	330,746
Gross margin	\$ 104,462	\$ 25,392	\$ 17,410	\$ 147,264
Gross margin percentage	27.2 %	47.9 %	43.2 %	30.8 %

	For the three-month period ended October 1, 2022			
	PDS	HHH	MS	Total
Revenue	\$ 355,620	\$ 49,853	\$ 37,536	\$ 443,009
Cost of revenue, excluding depreciation and amortization	254,756	32,968	\$ 20,702	308,426
Gross margin	\$ 100,864	\$ 16,885	\$ 16,834	\$ 134,583
Gross margin percentage	28.4 %	33.9 %	44.8 %	30.4 %

For the nine-month period ended September 30, 2023			
--	--	--	--

	PDS	HHH	MS	Total
Revenue	\$ 1,135,365	\$ 164,525	\$ 116,478	\$ 1,416,368
Cost of revenue, excluding depreciation and amortization	815,221	87,189	66,974	969,384
Gross margin	\$ 320,144	\$ 77,336	\$ 49,504	\$ 446,984
Gross margin percentage	28.2 %	47.0 %	42.5 %	31.6 %

For the nine-month period ended October 1, 2022

	PDS	HHH	MS	Total
Revenue	\$ 1,053,835	\$ 177,858	\$ 104,805	\$ 1,336,498
Cost of revenue, excluding depreciation and amortization	753,266	98,933	\$ 59,847	912,046
Gross margin	\$ 300,569	\$ 78,925	\$ 44,958	\$ 424,452
Gross margin percentage	28.5 %	44.4 %	42.9 %	31.8 %

1614

AVEANNA HEALTHCARE HOLDINGS INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

	For the three-month periods ended		For the nine-month periods ended	
	September 30,		September 30,	October 1,
	2023	October 1, 2022	2023	2022
Segment Reconciliation:				
Total segment gross margin	\$ 147,264	\$ 134,583	\$ 446,984	\$ 424,452
Branch and regional administrative expenses	91,004	89,542	273,967	267,283
Corporate expenses	27,446	33,215	84,735	105,984
Goodwill impairment	105,136	-	105,136	470,207
Depreciation and amortization	2,962	4,917	10,494	16,774
Acquisition-related costs	428	-	466	69

Other operating (income) expense	(3,360)	2,122	(6,593)	1,953
Operating (loss) income	(76,352)	4,787	(21,221)	(437,818)
Interest income	50	164	238	369
Interest expense	(39,599)	(28,462)	(113,542)	(73,745)
Other income	14,143	45,140	27,124	86,523
(Loss) income before income taxes	<u>\$ (101,758)</u>	<u>\$ 21,629</u>	<u>\$ (107,401)</u>	<u>\$ (424,671)</u>

For the three-month period ended March 30, 2024

	<u>PDS</u>	<u>HHH</u>	<u>MS</u>	<u>Total</u>
Revenue	\$ 395,009	\$ 54,613	\$ 41,031	\$ 490,653
Cost of revenue, excluding depreciation and amortization	294,874	25,639	24,286	344,799
Gross margin	<u>\$ 100,135</u>	<u>\$ 28,974</u>	<u>\$ 16,745</u>	<u>\$ 145,854</u>
Gross margin percentage	25.4 %	53.1 %	40.8 %	29.7 %

For the three-month period ended April 1, 2023

	<u>PDS</u>	<u>HHH</u>	<u>MS</u>	<u>Total</u>
Revenue	\$ 372,947	\$ 56,126	\$ 37,340	\$ 466,413
Cost of revenue, excluding depreciation and amortization	268,763	31,095	\$ 22,090	321,948
Gross margin	<u>\$ 104,184</u>	<u>\$ 25,031</u>	<u>\$ 15,250</u>	<u>\$ 144,465</u>
Gross margin percentage	27.9 %	44.6 %	40.8 %	31.0 %

For the three-month periods ended

Segment Reconciliation:	<u>March 30, 2024</u>	<u>April 1, 2023</u>
Total segment gross margin	\$ 145,854	\$ 144,465
Branch and regional administrative expenses	87,914	91,708
Corporate expenses	29,842	30,935
Depreciation and amortization	2,912	4,041
Acquisition-related costs	-	70
Other operating expense	2,320	72
Operating income	22,866	17,639
Interest income	102	75
Interest expense	(39,647)	(35,958)
Other income (expense)	18,169	(12,188)

Income (loss) before income taxes	\$	1,490	\$	(30,432)
-----------------------------------	----	-------	----	----------

14.13. NET (LOSS) INCOME LOSS PER SHARE

Basic net (loss) income loss per share is calculated by dividing net (loss) income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net (loss) income loss per share is calculated by dividing net (loss) income loss by the diluted weighted average number of shares of common stock outstanding for the period. For purposes of this calculation, outstanding stock options RSUs and PSUs are considered potential dilutive shares of common stock. The following is a computation of basic and diluted net (loss) income loss per share (amounts in thousands, except per share amounts):

	For the three-month periods ended		For the nine-month periods ended	
	September 30, 2023	October 1, 2022	September 30, 2023	October 1, 2022
Numerator:				
Net (loss) income	\$ (102,389)	\$ 24,298	\$ (108,788)	\$ (424,255)
Denominator:				
Weighted average shares of common stock outstanding (1), basic	189,139	186,113	189,632	185,327
Net (loss) income per share, basic	<u>\$ (0.54)</u>	<u>\$ 0.13</u>	<u>\$ (0.57)</u>	<u>\$ (2.29)</u>
Weighted average shares of common stock outstanding (1), diluted	189,139	186,166	189,632	185,327
Net (loss) income per share, diluted	<u>\$ (0.54)</u>	<u>\$ 0.13</u>	<u>\$ (0.57)</u>	<u>\$ (2.29)</u>
Dilutive securities outstanding not included in the computation of diluted net (loss) income per share, as their effect is antidilutive:				
RSUs	7,674	4,684	7,674	4,722
PSUs	4,059	1,368	4,059	1,368
Stock options	13,621	14,553	13,621	14,553

	For the three-month periods ended	
	March 30, 2024	April 1, 2023
Numerator:		
Net loss	\$ (11,172)	\$ (31,998)

Denominator:		
Weighted average shares of common stock outstanding ⁽¹⁾ , basic and diluted		
	192,241	189,054
Net loss per share, basic and diluted	\$ (0.06)	\$ (0.17)
Dilutive securities outstanding not included in the computation of diluted net loss per share, as their effect is antidilutive:		
RSUs	9,709	8,570
PSUs	6,558	4,620
Stock options	13,153	14,236

(1) The calculation of weighted average shares of common stock outstanding includes all vested deferred restricted stock units.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations, financial condition, liquidity and cash flows for the periods presented below. This discussion should be read in conjunction with the interim unaudited consolidated financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q and in conjunction with the audited consolidated financial statements and related notes, our “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in each case included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023 filed with the SEC. As discussed in the section above titled “Cautionary Note Regarding Forward-Looking Statements,” the following discussion contains forward-looking statements that are based upon our current expectations, including with respect to our future revenues and operating results. Our actual results may differ materially from those anticipated in such forward-looking statements as a result of various factors. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included under Part II, Item 1A below as well as in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023.

Unless otherwise provided, “Aveanna,” “we,” “our” and the “Company” refer to Aveanna Healthcare Holdings Inc. and its consolidated subsidiaries.

Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52-week or 53-week fiscal year. “Fiscal year 2023” 2024” refers to the 52-week fiscal year ending on December 30, 2023 December 28, 2024. “Fiscal year 2022” 2023” refers to the 52-week fiscal year ended on December 31, 2022 December 30, 2023. The “three-month period ended September 30, 2023 March 30, 2024”, or “third “first quarter of 2024” refers to the 13-week fiscal quarter ended on March 30, 2024. The “three-month period ended April 1, 2023” or “first quarter of 2023” refers to the 13-week fiscal quarter ended on September 30, 2023. The “three-month period ended October 1, 2022” or “third quarter of 2022” refers to the 13-week fiscal quarter ended on October 1, 2022. The “nine-month period ended September 30, 2023”, or “first nine months of 2023”, refers to the period from January 1, 2023 through September 30, 2023. The “nine-month period ended October 1, 2022”, or “first nine months of 2022”, refers to the period from January 2, 2022 through October 1, 2022 April 1, 2023.

Overview

We are a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations. We directly address the most pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home, the lower cost care setting preferred by patients. Our patient-centered care delivery platform is designed to improve the quality of care our patients receive, which allows them to remain in their homes and minimizes the overutilization of high-cost care settings such as hospitals. Our clinical model is led by our caregivers, primarily skilled nurses, who provide specialized care to address the complex needs of each patient we serve across the full range of patient populations: newborns, children, adults and seniors. We have invested significantly in our platform to bring together best-in-class talent at all levels of the organization and support such talent with industry leading training, clinical programs, infrastructure and technology-enabled systems, which are increasingly essential in an evolving healthcare industry. We believe our platform creates sustainable competitive advantages that support our ability to continue driving rapid growth, both organically and through acquisitions, and positions us as the partner of choice for the patients we serve.

Segments

We deliver our services to patients through three segments: Private Duty Services (“PDS”); Home Health & Hospice (“HHH”); and Medical Solutions (“MS”).

The following table summarizes the revenues generated by each of our segments for the three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively:

(dollars in thousands)	Consolidated		PDS		HHH		MS	
For the three-month period ended September 30, 2023	\$	478,010	\$	384,750	\$	52,989	\$	40,271
Percentage of consolidated revenue				81 %		11 %		8 %

For the three-month period ended October 1, 2022	\$	443,009	\$	355,620	\$	49,853	\$	37,536
Percentage of consolidated revenue				81 %		11 %		8 %

The following table summarizes the revenues generated by each of our segments for the nine-month periods ended September 30, 2023 and October 1, 2022, respectively:

18

(dollars in thousands)	Consolidated				Consolidated	PDS	HHH	MS
	idated	PDS	HHH	MS				
For the nine-month period ended September 30, 2023		1,13	164	116				
	1,416	5,36	,52	,47				
	\$,368	\$ 5	\$ 5	\$ 8				
For the three-month period ended March 30, 2024					\$ 490,653	\$ 395,009	\$ 54,613	\$ 41,031
Percentage of consolidated revenue		80 %	12 %	8 %		81 %	11 %	8 %
For the nine-month period ended October 1, 2022		1,05	177	104				
	1,336	3,83	,85	,80				
	\$,498	\$ 5	\$ 8	\$ 5				
For the three-month period ended April 1, 2023					\$ 466,413	\$ 372,947	\$ 56,126	\$ 37,340
Percentage of consolidated revenue		79 %	13 %	8 %		80 %	12 %	8 %

PDS Segment

Private Duty Services predominantly includes private duty nursing ("PDN") services, as well as pediatric therapy services. Our PDN patients typically enter our service as children, as our most significant referral sources for new patients are children's hospitals. It is common for our PDN patients to continue to receive our services into adulthood, as approximately 30% of our PDN patients are over the age of 18.

Our PDN services involve the provision of clinical and non-clinical hourly care to patients in their homes, which is the preferred setting for patient care. PDN services typically last four to 24 hours a day, provided by our registered nurses, licensed practical nurses, home health aides, and other non-clinical caregivers who are focused on providing high-quality short-term and long-term clinical care to

16

medically fragile children and adults with a wide variety of serious illnesses and conditions. Patients who typically qualify for our PDN services include those with the following conditions:

- Tracheotomies or ventilator dependence;
- Dependence on continuous nutritional feeding through a “G-tube” or “NG-tube”;
- Dependence on intravenous nutrition;
- Oxygen-dependence in conjunction with other medical needs; and
- Complex medical needs such as frequent seizures.

Our PDN services include:

- In-home skilled nursing services to medically fragile children and adults;
- Nursing services in school settings in which our caregivers accompany patients to school;
- Services to patients in our Pediatric Day Healthcare Centers (“PDHC”); and
- Non-clinical care, including programs such as employer of record support services and personal care services.

Through our pediatric therapy services, we provide a valuable multidisciplinary approach that we believe serves all of a child’s therapy needs. We provide both in-clinic and home-based therapy services to our patients. Our therapy services include physical, occupational and speech services. We regularly collaborate with physicians and other community healthcare providers, which allows us to provide more comprehensive care.

HHH Segment

Our Home Health and Hospice segment predominantly includes home health services, as well as hospice and specialty program services. Our HHH patients typically enter our service as seniors, and our most significant referral sources for new patients are hospitals, physicians and long-term care facilities.

Our home health services involve the provision of in-home services to our patients by our clinicians which may include nurses, therapists, social workers and home health aides. Our caregivers work with our patients’ physicians to deliver a personalized plan of care to our patients in their homes. Home healthcare can help our patients recover after a hospitalization or surgery and assist patients in managing chronic illnesses. We also help our patients manage their medications. Through our care, we help our patients recover more fully in the comfort of their own homes, while remaining as independent as possible. Our home health services include: in-home skilled nursing services; physical, occupational and speech therapy; medical social services and aide services.

Our hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Our hospice care is a positive, empowering form of care designed to provide comfort and support to our patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The goal of hospice is to neither prolong life nor hasten death, but to help our patients live as dignified and pain-free as possible. Our hospice care is provided by a team of specially trained professionals in a variety of living situations, including at home, at the hospital, a nursing home, or an assisted living facility.

MS Segment

Through our Medical Solutions segment, we offer a comprehensive line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. We provide our patients with access to one of the largest selections of enteral

19

formulas, supplies and pumps in our industry, with more than 300 nutritional formulas available. Our registered nurses, registered dietitians and customer service technicians support our patients 24 hours per day, 365 days per year, in-hospital, at-home, or remotely to help ensure that our patients have the best nutrition assessments, change order reviews and formula selection expertise.

Factors Affecting Results of Operations and Comparability Recent Developments

American Rescue Plan Act ("ARPA")

On March 11, 2021 President Biden signed ARPA into law. ARPA is a federal stimulus bill designed to aid public health and economic recovery from the COVID-19 pandemic. ARPA includes \$350 billion in emergency funding for state, local, territorial and tribal governments, known as the Coronavirus State and Local Fiscal Recovery Funds ("ARPA Recovery Funds"). States must obligate the ARPA Recovery Funds by December 31, 2024 and spend such funds by December 31, 2026. Usage of the ARPA Recovery Funds is subject to the requirements specified in the United States Treasury Department's CMS Final Rule issued on January 6, 2022 (the "Final Rule").

The Final Rule provides states with substantial flexibility in utilizing ARPA Relief Funds, including to support public health expenditures, such as vaccination programs and testing, and PPE purchases, as well as providing premium pay for essential workers, including those in home-care settings, among many other things. States may not use ARPA Recovery Funds to fund tax cuts, fund budget deficits, or to support public employee pensions. We recognized ARPA Recovery funds from various states in revenue in our consolidated statements of operations of \$2.9 million and \$6.6 million for the three and nine-month periods ended September 30, 2023, respectively, and \$1.9 million and \$5.5 million for the three and nine-month periods ended October 1, 2022, respectively. We may receive additional ARPA Recovery Funds in the future; however, we cannot estimate the amount or timing of any future receipts. These funds are not subject to repayment, provided we are able to attest to and comply with any terms and conditions of such funding, as applicable. If we are unable to attest to or comply with current or future terms and conditions, our ability to retain some or all of the ARPA Recovery Funds received may be impacted.

HHS Proposed Rule: "Ensuring Access to Medicaid Services"

On April 27, 2023 April 22, 2024, the U.S. Department of Health & Human Services through the Centers for Medicare and Medicaid Services ("HHS" CMS) introduced a proposed rule titled "Assuring released the "Ensuring Access to Medicaid Services." Services" final rule (CMS-2442-F). The proposed final rule has a stated goal of improving access to services for Medicaid beneficiaries. As part of this proposed rule, HHS is proposing CMS requires that state Medicaid agencies departments provide assurances that a minimum of 80% of Medicaid payments for personal care and similar

services be spent on compensation to and clinical supervision of the direct care workers. The proposed workers providing these services. While the effective date of the final rule would allow is July 9, 2024, the states four are allowed six years to implement changes required by a final rule, with extended time specified for managed care delivery systems. The proposed rule was subject to comment, and HHS specifically requested comments on the provisions regarding the 80% threshold, related definitions and the implementation period. The public comment period concluded on July 3, 2023. minimum payment. The ultimate impact of any the final rule which could be adverse for periods after implementation, but could also benefit is not expected to have a material impact to our business by improving access to services, depends on the requirements set forth in any final rule. results of operations.

17

Important Operating Metrics

We review the following important metrics on a segment basis and not on a consolidated basis:

PDS and MS Segment Operating Metrics

Volume

Volume represents PDS hours of care provided and MS unique patients served, which is how we measure the amount of our patient services provided. We review the number of hours of PDS care provided on a weekly basis and the number of MS unique patients served on a weekly basis. We believe volume is an important metric because it helps us understand how the Company is growing in each of these segments through strategic planning and acquisitions. We also use this metric to inform strategic decision making in determining opportunities for growth.

Revenue Rate

For our PDS and MS segments, revenue rate is calculated as revenue divided by PDS hours of care provided or the number of MS unique patients served, respectively. We believe revenue rate is an important metric because it represents the amount of revenue we receive per

20

PDS hour of patient service or per individual MS patient transaction and helps management assess the amount of fees that we are able to bill for our services. Management uses this metric to assess how effectively we optimize reimbursement rates.

Cost of Revenue Rate

For our PDS and MS segments, cost of revenue rate is calculated as cost of revenue divided by PDS hours of care provided or the number of MS unique patients served, respectively. We believe cost of revenue rate is an important metric because it helps us understand the cost per PDS hour of patient service or per individual MS patient transaction. Management uses this metric to understand how effectively we manage labor and product costs.

Spread Rate

For our PDS and MS segments, spread rate represents the difference between the respective revenue rates and cost of revenue rates. Spread rate is an important metric because it helps us better understand the margins being recognized per PDS hour of patient service or per individual MS patient transaction. Management uses this metric to assess how successful we have been in optimizing reimbursement rates, managing labor and product costs, and assessing opportunities for growth.

HHH Segment Operating Metrics

Home Health Total Admissions and Home Health Episodic Admissions

Home health total admissions represents the number of new patients who have begun receiving services. We review the number of home health admissions on a daily basis as we believe it is a leading indicator of our growth. We measure home health admissions by reimbursement structure, separating them into home health episodic admissions and fee-for-service admissions (other admissions), which allows us to better understand the payor mix of our home health business.

Home Health Total Episodes

Home health total episodes represents the number of episodic admissions and episodic recertifications to capture patients who have either started to receive services or have been recertified for another episode of care. Management reviews home health total episodes on a monthly basis as to understand the volume of patients who were authorized to receive care during the month.

Home Health Revenue Per Completed Episode

Home health revenue per completed episode is calculated by dividing total payments received from completed episodes by the number of completed episodes during the period. Episodic payments are determined by multiple factors including type of referral source, patient

21

diagnoses, and utilization. Management tracks home health revenue per completed episode over time to evaluate both the clinical and financial profile of the business in a single metric.

Results of Operations

18

Three-Month Period Ended September 30, 2023 March 30, 2024 Compared to the Three-Month Period Ended October 1, 2022 April 1, 2023

The following table summarizes our consolidated results of operations, including Field contribution, which is a non-GAAP measure (see “Non-GAAP Financial Measures” below), for the three-month periods indicated:

	For the three-month periods ended					
	September 30, 2023	% of Revenue	October 1, 2022	% of Revenue	Change	% Change
<i>(dollars in thousands)</i>						
Revenue	\$ 478,010	100.0 %	\$ 443,009	100.0 %	\$ 35,001	7.9 %
Cost of revenue, excluding depreciation and amortization	330,746	69.2 %	308,426	69.6 %	22,320	7.2 %
Gross margin	\$ 147,264	30.8 %	\$ 134,583	30.4 %	\$ 12,681	9.4 %
Branch and regional administrative expenses	91,004	19.0 %	89,542	20.2 %	1,462	1.6 %
Field contribution	\$ 56,260	11.8 %	\$ 45,041	10.2 %	\$ 11,219	24.9 %
Corporate expenses	27,446	5.7 %	33,215	7.5 %	(5,769)	-17.4 %
Goodwill impairment	105,136	22.0 %	-	0.0 %	105,136	-
Depreciation and amortization	2,962	0.6 %	4,917	1.1 %	(1,955)	-39.8 %
Acquisition-related costs	428	0.1 %	-	0.0 %	428	-
Other operating (income) expense	(3,360)	-0.7 %	2,122	0.5 %	(5,482)	-258.3 %
Operating (loss) income	\$ (76,352)	-16.0 %	\$ 4,787	1.1 %	\$ (81,139)	NM
Interest expense, net	(39,549)		(28,298)		(11,251)	39.8 %
Other income	14,143		45,140		(30,997)	-68.7 %
Income tax (expense) benefit	(631)		2,669		(3,300)	-123.6 %
Net (loss) income	\$ (102,389)		\$ 24,298		\$ (126,687)	521.4 %

NM = A percentage calculation that is not meaningful due to a percentage change greater than 1000%.

	For the three-month periods ended					
	March 30, 2024	% of Revenue	April 1, 2023	% of Revenue	Change	% Change
<i>(dollars in thousands)</i>						
Revenue	\$ 490,653	100.0 %	\$ 466,413	100.0 %	\$ 24,240	5.2 %

Cost of revenue, excluding depreciation and amortization	344,799	70.3 %	321,948	69.0 %	22,851	7.1 %
Gross margin	\$ 145,854	29.7 %	\$ 144,465	31.0 %	\$ 1,389	1.0 %
Branch and regional administrative expenses	87,914	17.9 %	91,708	19.7 %	(3,794)	-4.1 %
Corporate expenses	29,842	6.1 %	30,935	6.6 %	(1,093)	-3.5 %
Depreciation and amortization	2,912	0.6 %	4,041	0.9 %	(1,129)	-27.9 %
Acquisition-related costs	-	0.0 %	70	0.0 %	(70)	-100.0 %
Other operating expense	2,320	0.5 %	72	0.0 %	2,248	NM
Operating income	\$ 22,866	4.7 %	\$ 17,639	3.8 %	\$ 5,227	29.6 %
Interest expense, net	(39,545)		(35,883)		(3,662)	10.2 %
Other income (expense)	18,169		(12,188)		30,357	249.1 %
Income tax expense	(12,662)		(1,566)		(11,096)	708.6 %
Net loss	\$ (11,172)		\$ (31,998)		\$ 20,826	65.1 %

The following table summarizes our consolidated key performance measures, including Field contribution and Field contribution margin, which are non-GAAP measures (see “Non-GAAP Financial Measures” below), for the three-month periods indicated:

	For the three-month periods ended				For the three-month periods ended			
	September 30, 2023	October 1, 2022	Change	% Change	March 30, 2024	April 1, 2023	Change	% Change
(dollars in thousands)								
Revenue	478,010	443,009	35,001	7.9 %	490,653	466,413	\$ 24,240	5.2 %
Cost of revenue, excluding depreciation and amortization	330,746	308,426	22,320	7.2 %	344,799	321,948	22,851	7.1 %
Gross margin	147,264	134,583	12,681	9.4 %	145,854	144,465	\$ 1,389	1.0 %
Gross margin percentage	30.8 %	30.4 %			29.7 %	31.0 %		

Branch and regional administrative expenses	89,542	1,462	1.6%	87,914	91,708	(3,794)	-4.1%
Field contribution	45,041	21,249	9%	57,940	52,757	5,183	9.8%
Field contribution margin	11.8%	10.2%		11.8%	11.3%		
Corporate expenses	(5,332)	76	-17.4%	29,842	30,935	(1,093)	-3.5%
As a percentage of revenue	5.7%	7.5%		6.1%	6.6%		
Operating (loss) income	(81,135)	4,787	9)	NM			
Operating income				\$ 22,866	\$ 17,639	\$ 5,227	29.6%
As a percentage of revenue	-16.0%	1.1%		4.7%	3.8%		

NM = A percentage calculation that is not meaningful due to a percentage change greater than 1000%

.19

The following tables summarize our key performance measures by segment for the three-month periods indicated:

22

(dollars and hours in thousands)	PDS				PDS			
	For the three-month periods ended				For the three-month periods ended			
	Septemb	Octobe		%	March 30,	April 1,		%
	er 30, 2023	r 1, 2022	Change	Change	2024	2023	Change	Change

Revenue	29								
	384,75	355,6	,1						
	\$ 0	\$ 20	\$ 30	8.2 %	\$ 395,009	\$ 372,947	\$ 22,062	5.9 %	
Cost of revenue, excluding depreciation and amortization	25								
	280,28	254,7	,5	10.					
	8	56	32	0 %	294,874	268,763	26,111	9.7 %	
Gross margin	3,								
	104,46	100,8	59						
	\$ 2	\$ 64	\$ 8	3.6 %	\$ 100,135	\$ 104,184	\$ (4,049)	-3.9 %	
Gross margin percentage				((4)
	27.2 %	28.4 %	-1.2 %)	4	25.4 %	27.9 %		-2.5 %	
Hours	43								
	10,090	9,652	8	4.5 %	10,264	9,783	481	4.9 %	
Revenue rate				((1)
	1.			1					
	\$ 38.13	\$ 36.84	\$ 29	3.7 %)	\$ 38.48	\$ 38.12	\$ 0.36	1.0 %	
Cost of revenue rate				((2)
	1.			2					
	\$ 27.78	\$ 26.39	\$ 39	5.5 %)	\$ 28.73	\$ 27.47	\$ 1.26	4.8 %	
Spread rate				((3)
	(0.			3					
	\$ 10.35	\$ 10.45	\$ 10)	-0.9 %)	\$ 9.75	\$ 10.65	\$ (0.90)	-8.8 %	
	HHH				HHH				
	For the three-month periods ended				For the three-month periods ended				
(dollars and admissions/episodes in thousands)	Septemb	Octobe	%		March 30,	April 1,	%		
	er 30,	r 1,	Cha	Cha	2024	2023	Change	Change	
	2023	2022	nge	nge					
Revenue			3,						
		49,85	13						
	\$ 52,989	\$ 3	\$ 6	6.3 %	\$ 54,613	\$ 56,126	\$ (1,513)	-2.7 %	
Cost of revenue, excluding depreciation and amortization			(5,						
		32,96	37	-16.					
	27,597	8	1)	3 %	25,639	31,095	(5,456)	-17.5 %	

Gross margin	8,16,885050.							
	\$ 25,392	\$ 5	\$ 7	4 %	\$ 28,974	\$ 25,031	\$ 3,943	15.8 %
Gross margin percentage	(14.4 %)				(4) 8.5 %			
	47.9 %	33.9 %	0 %)		53.1 %	44.6 %		
Home health total admissions ⁽⁵⁾	(2. -17.9.311.30) 7 %				10.1	11.7	(1.6)	-13.7 %
Home health episodic admissions ⁽⁶⁾	7.0	7.0	-	0.0 %	7.6	8.0	(0.4)	-5.0 %
Home health total episodes ⁽⁷⁾	(0.11.211.42) -1.8 %				12.1	11.9	0.2	1.7 %
Home health revenue per completed episode ⁽⁸⁾	\$ 3,046	\$ 3,023	\$ 23	0.8 %	\$ 3,070	\$ 2,969	\$ 101	3.4 %
	MS				MS			
	For the three-month periods ended				For the three-month periods ended			
	Septemb	Octobe	%					
(dollars and UPS in thousands)	er 30, 2023	r 1, 2022	Cha	Cha	March 30, 2024	April 1, 2023	Change	% Change
Revenue	2,37,5373							
	\$ 40,271	\$ 6	\$ 5	7.3 %	\$ 41,031	\$ 37,340	\$ 3,691	9.9 %
Cost of revenue, excluding depreciation and amortization	2,20,701510.22,861294 %				24,286	22,090	2,196	9.9 %
Gross margin	16,8357							
	\$ 17,410	\$ 4	\$ 6	3.4 %	\$ 16,745	\$ 15,250	\$ 1,495	9.8 %
Gross margin percentage	(4) 43.2 % 44.8 % -1.6 %)				40.8 %	40.8 %		
Unique patients served ("UPS")	88	81	7	8.6 %	92	85	7	8.2 %

Revenue rate										(1)
		463.4	(5.	1						
	\$ 457.63	\$ 1	\$ 78)	-1.3%)	\$	445.99	\$	439.29	\$ 6.70	1.7 %
Cost of revenue rate										(2)
		255.5	4.	2						
	\$ 259.78	\$ 8	\$ 20	1.8%)	\$	263.98	\$	259.88	\$ 4.10	1.7 %
Spread rate										(3)
		207.8	(9.	3						
	\$ 197.84	\$ 3	\$ 98)	-5.2%)	\$	182.01	\$	179.41	\$ 2.60	1.6 %

- (1) Represents the period over period change in revenue rate, plus the change in revenue rate attributable to the change in volume.
- (2) Represents the period over period change in cost of patient services rate, plus the change in cost of patient services rate attributable to the change in volume.
- (3) Represents the period over period change in spread rate, plus the change in spread rate attributable to the change in volume.
- (4) Represents the change in margin percentage year over year.
- (5) Represents home health episodic and fee-for-service admissions.
- (6) Represents home health episodic admissions.
- (7) Represents episodic admissions and recertifications.
- (8) Represents Medicare revenue per completed episode.

The following discussion of our results of operations should be read in conjunction with the foregoing tables summarizing our consolidated results of operations and key performance measures, as well as our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended **December 31, 2022** **December 30, 2023**.

Summary Operating Results

Operating **(Loss)** **Income**

23 **20**

Operating **loss** **income** was **\$76.4 million** **\$22.9 million** for the three-month period ended **September 30, 2023** **March 30, 2024**, as compared to **an operating income of \$4.8 million, or 1.1% of revenue, \$17.6 million** for the three-month period

ended **October 1, 2022** **April 1, 2023**, a decrease **an increase** of **\$81.1 million** **\$5.2 million**, primarily driven by a **\$105.1 million non-cash charge for goodwill impairment recorded in the third quarter of 2023**. **or 29.6%**.

Operating **loss** **income** for the **third first fiscal** quarter of **2023** **2024** was positively impacted by an increase of **\$11.2 million** **\$5.2 million**, or **24.9%** **9.8%**, in Field contribution as compared to the **third first fiscal** quarter of **2022**. **2023**. The **\$11.2 million** **\$5.2 million** increase in Field contribution resulted from a **\$35.0 million** **\$24.2 million**, or **7.9%** **5.2%**, increase in consolidated revenue and a **1.6%** **0.5%** increase in our Field contribution margin to 11.8% for the **third first fiscal** quarter of **2023** **2024** from **10.2%** **11.3%** for the **third first fiscal** quarter of **2022**. **2023**. The primary driver of our higher Field contribution margin year over the comparable quarter year was a **0.4% increase** **1.8% decrease** in gross margin branch and regional administrative expenses as a percentage of revenue to **30.8%** **17.9%** for the **third first fiscal** quarter of **2023** **2024** from **30.4%** **19.7%** for the **third first fiscal** quarter of **2022**. **2023**.

In addition to the **\$11.2 million** **The overall \$5.2 million** increase in Field contribution, the following additional items primarily contributed to the overall **\$81.1 million decrease** in operating income over the comparable **third quarter periods**: **periods** primarily consists of:

- the **\$105.1 million non-cash charge for goodwill impairment**; **previously discussed \$5.2 million increase in operating income**;
- a **\$5.8 million** **\$1.1 million** decrease in corporate expenses;
- a **\$5.5 million** **\$1.1 million** decrease in depreciation and amortization; offset by
- a **\$2.2 million** increase in other operating **(income) expense**; and
- a **\$2.0 million** decrease in depreciation and amortization. **expense**.

Net **(Loss) Income** **Loss**

Net loss for the three-month period ended **September 30, 2023** **March 30, 2024** was **\$102.4 million** **\$11.2 million**, as compared to net **income** **loss** of **\$24.3 million** **\$32.0 million** for the three-month period ended **October 1, 2022** **April 1, 2023**. The **\$126.7 million** **\$20.8 million** decrease in net **income** **loss** was primarily driven by the following:

- the previously discussed **\$81.1 million decrease** **\$5.2 million increase** in operating income; and
- an aggregate **\$31.0 million decrease** **\$30.4 million increase** in valuation gains on interest rate derivatives, **increases in** net settlements received from interest rate derivative counterparties over the comparable **quarter**; **periods**; offset by
- a **\$3.3 million** increase in tax expense (benefit); and
- a **\$11.3 million** **\$3.7 million** increase in interest expense, net of interest **income**. **income**; and
- an **\$11.1 million** increase in income tax expense.

Revenue

Revenue was **\$478.0 million** **\$490.7 million** for the three-month period ended **September 30, 2023** **March 30, 2024**, as compared to **\$443.0 million** **\$466.4 million** for the three-month period ended **October 1, 2022** **April 1, 2023**, an increase of **\$35.0 million** **\$24.2 million**, or **7.9%** **5.2%**. This increase resulted from the following segment activity:

- a \$29.1 million \$22.1 million, or 8.2% 5.9%, increase in PDS revenue;
- a \$3.1 million \$1.5 million, or 6.3% 2.7%, increase decrease in HHH revenue; and
- a \$2.7 million \$3.7 million, or 7.3% 9.9%, increase in MS revenue.

Our PDS segment revenue growth of \$29.1 million \$22.1 million, or 8.2% 5.9%, for the three-month period ended September 30, 2023 March 30, 2024 was attributable to a 4.5% 4.9% increase in volume and a 3.7% 1.0% increase in revenue rate. The 4.5% 4.9% increase in volume is was primarily attributable to growth in demand for non-clinical services.

The 3.7% 1.0% increase in PDS revenue rate for the three-month period ended September 30, 2023 March 30, 2024, as compared to the three-month period ended October 1, 2022 April 1, 2023, resulted primarily from reimbursement rate increases issued by various state Medicaid programs and Managed Medicaid payers, payers, offset by increases in implicit price concessions.

Our HHH segment revenue increase decrease of \$3.1 million \$1.5 million, or 6.3% 2.7%, for the three-month period ended September 30, 2023 March 30, 2024 resulted primarily from an improvement in implicit price concessions compared to the comparable period, partially offset by a decline in volumes over the comparable period. While home health total admissions declined 13.7% over the comparable period, total segment revenue declined by a lower rate primarily due to improvements in home health episodic mix.

The \$2.7 million \$3.7 million, or 7.3% 9.9%, increase in MS segment revenue for the three-month period ended September 30, 2023 March 30, 2024, as compared to the three-month period ended October 1, 2022 April 1, 2023, was attributable to volume growth of 8.6% partially offset by 8.2% combined with a 1.3% decrease 1.7% increase in revenue rate over the comparable period.

Cost of Revenue, Excluding Depreciation and Amortization

Cost of revenue, excluding depreciation and amortization, was \$330.7 million \$344.8 million for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$308.4 million \$321.9 million for the three-month period ended October 1, 2022 April 1, 2023, an increase of \$22.3 million \$22.9 million, or 7.2% 7.1%. This increase resulted from the following segment activity:

24

21

- a \$25.5 million \$26.1 million, or 10.0% 9.7%, increase in PDS cost of revenue;
- a \$5.4 million \$5.5 million, or 16.3% 17.5%, decrease in HHH cost of revenue; and
- a \$2.2 million, or 10.4% 9.9%, increase in MS cost of revenue.

The 10.0% 9.7% increase in PDS cost of revenue for the three-month period ended September 30, 2023 March 30, 2024 resulted from the previously described 4.5% 4.9% increase in PDS volume combined with a 5.5% 4.8% increase in PDS cost of revenue rate. The 5.5% 4.8% increase in cost of revenue rate primarily resulted from higher caregiver labor costs, including the pass-through of state reimbursement rate increases.

The 16.3% 17.5% decrease in HHH cost of revenue for the three-month period ended September 30, 2023 March 30, 2024 was driven primarily driven by a decline in HHH volumes as well as lower overall and improvements in HHH caregiver costs as a percentage of revenue. utilization.

The 10.4% 9.9% increase in MS cost of revenue for the three-month period ended September 30, 2023 March 30, 2024 was driven by the previously described 8.6% 8.2% growth in MS volumes during the third quarter of 2022 and a 1.8% 1.7% increase in cost of revenue rate.

Gross Margin and Gross Margin Percentage

Gross margin was \$147.3 million \$145.9 million, or 30.8% 29.7% of revenue, for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$134.6 million \$144.5 million, or 30.4% 31.0% of revenue, for the three-month period ended October 1, 2022 April 1, 2023. Gross margin increased \$12.7 million \$1.4 million, or 9.4% 1.0%, from the comparable prior year quarter. The 0.4% increase 1.3% decrease in gross margin percentage for the three-month period ended September 30, 2023 March 30, 2024 resulted from the combined changes in our revenue rates and cost of revenue rates in each of our segments, which we refer to as the change in our spread rate, as follows:

- a 0.9% an 8.8% decrease in PDS spread rate from \$10.45 \$10.65 to \$10.35 \$9.75 driven by the 3.7% 1.0% increase PDS revenue rate, net of the 5.5% 4.8% increase in PDS cost of revenue rate;
- a 5.2% decrease 1.6% increase in MS spread rate from \$207.83 \$179.41 to \$197.84 \$182.01 driven by the 1 decrease 1.7% increase in MS revenue rate, net of the 1.8% 1.7% increase in MS cost of revenue rate; and
- our HHH segment, in which gross margin percentage increased by 14.0% 8.5%.

Branch and Regional Administrative Expenses

Branch and regional administrative expenses were \$91.0 million \$87.9 million, or 19.0% 17.9% of revenue, for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$89.5 million \$91.7 million, or 20.2% 19.7% of revenue, for the three-month period ended October 1, 2022 April 1, 2023, an increase a decrease of \$1.5 million \$3.8 million, or 1.6% 4.1%.

The 1.6% increase 4.1% decrease in branch and regional administrative expenses was lower than our 7.9% revenue growth for the three-month period ended September 30, 2023 March 30, 2024, as compared to the three-month period ended October 1, 2022 April 1, 2023, was primarily due to the positive effects of restructuring portions of our branch and

regional operating structure, and lower integration costs in the current year quarter, as the integration of our acquisitions in the HHH segment effected in 2021 (the "2021 HHH Acquisitions") was completed in the second half of 2022. These factors which resulted in the overall 1.2% 1.8% decrease in branch and regional administrative expenses as a percentage of revenue during the comparable quarterly three-month periods.

Field Contribution and Field Contribution Margin

Field contribution was \$56.3 million \$57.9 million, or 11.8% of revenue, for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$45.0 million \$52.8 million, or 10.2% 11.3% of revenue, for the three-month period ended October 1, 2022 April 1, 2023. Field contribution increased \$11.2 million \$5.2 million, or 24.9% 9.8%, for the three-month period ended September 30, 2023 March 30, 2024, as compared to the three-month period ended October 1, 2022 April 1, 2023. The 1.6% 0.5% increase in Field contribution margin for the three-month period ended September 30, 2023 March 30, 2024 resulted from the following:

- the 0.4% increase in gross margin percentage in the three-month period ended September 30, 2023, as compared to the three-month period ended October 1, 2022; and
- the 1.2% a 1.8% decrease in branch and regional administrative expenses as a percentage of revenue for in three-month period ended September 30, 2023 March 30, 2024, as compared to the three-month period ended October 1, 2022 April 1, 2023; offset by
- a 1.3% decrease in gross margin percentage in the three-month period ended March 30, 2024, as compared to the three-month period ended April 1, 2023.

Field contribution and Field contribution margin are non-GAAP financial measures. See "Non-GAAP Financial Measures" below.

Corporate Expenses

Corporate expenses as a percentage of revenue for the three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023 were as follows:

25	22
----	----

For the three-month periods ended	
September 30, 2023	October 1, 2022

(dollars in thousands)				
	Amount	% of Revenue	Amount	% of Revenue
Revenue	\$ 478,010		\$ 443,009	
Corporate expense components:				
Compensation and benefits	\$ 14,593	3.1 %	\$ 15,274	3.4 %
Non-cash share-based compensation	2,513	0.5 %	2,259	0.5 %
Professional services	4,492	0.9 %	8,576	1.9 %
Rent and facilities expense	3,301	0.7 %	3,362	0.8 %
Office and administrative	482	0.1 %	837	0.2 %
Other	2,065	0.5 %	2,907	0.7 %
Total corporate expenses	\$ 27,446	5.7 %	\$ 33,215	7.5 %

For the three-month periods ended				
	March 30, 2024		April 1, 2023	
	Amount	% of Revenue	Amount	% of Revenue
(dollars in thousands)				
Revenue	\$ 490,653		\$ 466,413	
Corporate expense components:				
Compensation and benefits	\$ 15,878	3.2 %	\$ 16,765	3.6 %
Non-cash share-based compensation	2,423	0.5 %	2,161	0.5 %
Professional services	6,313	1.3 %	5,973	1.3 %
Rent and facilities expense	3,013	0.6 %	2,861	0.6 %
Office and administrative	577	0.1 %	217	0.0 %
Other	1,638	0.3 %	2,958	0.6 %
Total corporate expenses	\$ 29,842	6.1 %	\$ 30,935	6.6 %

Corporate expenses were \$27.4 million \$29.8 million, or 5.7% 6.1% of revenue, for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$33.2 million \$30.9 million, or 7.5% 6.6% of revenue, for the three-month period ended October 1, 2022 April 1, 2023. The \$5.8 million \$1.1 million, or 17.4% 3.5%, decrease in corporate expenses resulted primarily from:

- from lower compensation and benefits costs due to a reduction in transition and integration activities with acquired businesses, as well as the executive transition completed on December 31, 2022; and
- lower professional service costs due to a reduction in transition and integration activities.

Goodwill Impairment

Goodwill impairment was \$105.1 million for the three-month period ended September 30, 2023. As a result of anticipated volume not being actualized to forecasted levels in the reporting unit within our HHH segment, primarily related to continued challenges in the labor markets, we recorded a \$105.1 million non-cash goodwill impairment charge during the

three months ended September 30, 2023 lower public company insurance costs. There was no goodwill impairment charge recorded in the comparable quarterly period ended October 1, 2022. Please see Note 4 -Goodwill, to the interim unaudited consolidated financial statements, contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Depreciation and Amortization

Depreciation and amortization was \$3.0 million \$2.9 million for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$4.9 million \$4.0 million for the three-month period ended October 1, 2022 April 1, 2023, a decrease of \$2.0 million \$1.1 million, or 39.8% 27.9%. The \$2.0 million \$1.1 million decrease primarily resulted from the absence of amortization charges associated with assets acquired in connection with the acquisition of Comfort Care and Accredited completed in the fourth quarter of 2021 which were amortized over a one-year period. improved capital asset management.

Other Operating (Income) Expense

Other operating income expense was \$3.4 million \$2.3 million for the three-month period ended September 30, 2023 March 30, 2024, as compared to other operating expense of \$2.1 million \$0.1 million for the three-month period ended October 1, 2022 April 1, 2023, an increase of \$5.5 million \$2.2 million. The \$5.5 million \$2.2 million increase primarily resulted from an impairment of a \$5.1 million non-cash gain on the acquisition of certain business licenses and other net assets recorded during the third quarter of 2023, and a decrease in license impairment charges facility lease asset recorded in the comparable periods. current fiscal quarter.

Interest Expense, net of Interest Income

Interest expense, net of interest income was \$39.5 million for the three-month period ended September 30, 2023 March 30, 2024, as compared to \$28.3 million \$35.9 million for the three-month period ended October 1, 2022 April 1, 2023, an increase of \$11.3 million \$3.7 million, or 39.8% 10.2%. The increase was primarily driven by significant higher interest rates due to continued increases in interest rates, largely because the Federal Reserve Board has significantly increased the U.S. federal funds rate since the beginning of 2022. and slightly higher borrowing under our Securitization Facility. See further analysis under *Liquidity and Capital Resources* below.

Other Income (Expense)

Other income was \$14.1 million \$18.2 million for the three-month period ended September 30, 2023 March 30, 2024, as compared to other income expense of \$45.1 million \$12.2 million for the three-month period ended October 1, 2022, an decrease of \$31.0 million April 1, 2023. We realized a \$40.5 million decrease \$26.8 million increase in non-cash valuation gains on interest rate derivatives resulting from changes in market expectations of future interest rates as of the comparable quarter-end valuation dates and a \$9.6 million \$3.0 million improvement in net settlements with interest rate

derivative counterparties as interest rates increased compared to the prior year quarter period due to higher market interest rates. Details of other income (expense) included the following:

26

(dollars in thousands)	For the three-month periods ended	
	September 30,	
	2023	October 1, 2022
Valuation gain to state interest rate derivatives at fair value	\$ 4,322	\$ 44,845
Net settlements received from interest rate derivative counterparties	9,797	193
Other	24	102
Total other income	\$ 14,143	\$ 45,140

(dollars in thousands)	For the three-month periods ended	
	March 30, 2024	
	March 30, 2024	April 1, 2023
Valuation (loss) gain to state interest rate derivatives at fair value	\$ 8,276	\$ (18,537)
Net settlements received from (paid to) interest rate derivative counterparties	9,641	6,615
Other	252	(266)
Total other income (expense)	\$ 18,169	\$ (12,188)

Income Taxes

We incurred income tax expense of \$0.6 million \$12.7 million for the three-month period ended September March 30, 2023 2024, as compared to income tax benefit expense of \$2.7 million \$1.6 million for the three-month period ended October 1, 2022. This decrease in tax benefit was primarily driven by the changes in federal and state valuation allowances, and changes to federal and state current tax expense.

Nine-Month Period Ended September 30, 2023 Compared to the Nine-Month Period Ended October 1, 2022

The following table summarizes our consolidated results of operations, including Field contribution, which is a non-GAAP measure (see "Non-GAAP Financial Measures" below), for the nine-month periods indicated:

(dollars in thousands)	For the nine-month periods ended					
	September	% of	October 1,	% of		
	30, 2023	Revenue	2022	Revenue	Change	Change
Revenue	\$ 1,416,368	100.0 %	\$ 1,336,498	100.0 %	\$ 79,870	6.0 %
Cost of revenue, excluding depreciation and amortization	969,384	68.4 %	912,046	68.2 %	57,338	6.3 %

Gross margin	\$ 446,984	31.6 %	\$ 424,452	31.8 %	\$ 22,532	5.3 %
Branch and regional administrative expenses	273,967	19.3 %	267,283	20.0 %	6,684	2.5 %
Field contribution	\$ 173,017	12.2 %	\$ 157,169	11.8 %	\$ 15,848	10.1 %
Corporate expenses	84,735	6.0 %	105,984	7.9 %	(21,249)	-20.0 %
Goodwill impairment	105,136	7.4 %	470,207	35.2 %	(365,071)	-77.6 %
Depreciation and amortization	10,494	0.7 %	16,774	1.3 %	(6,280)	-37.4 %
Acquisition-related costs	466	0.0 %	69	0.0 %	397	575.4 %
Other operating (income) expense	(6,593)	-0.5 %	1,953	0.1 %	(8,546)	-437.6 %
Operating loss	\$ (21,221)	-1.5 %	\$ (437,818)	-32.8 %	\$ 416,597	-95.2 %
Interest expense, net	(113,304)		(73,376)		(39,928)	54.4 %
Other income	27,124		86,523		(59,399)	-68.7 %
Income tax (expense) benefit	(1,387)		416		(1,803)	-433.4 %
Net loss	\$ (108,788)		\$ (424,255)		\$ 315,467	-74.4 %

The following table summarizes our consolidated key performance measures, including Field contribution and Field contribution margin, which are non-GAAP measures (see “Non-GAAP Financial Measures” below), for the nine-month periods indicated:

(dollars in thousands)	For the nine-month periods ended			
	September 30,	October 1,	Change	% Change
	2023	2022		
Revenue	\$ 1,416,368	\$ 1,336,498	\$ 79,870	6.0 %
Cost of revenue, excluding depreciation and amortization	969,384	912,046	57,338	6.3 %
Gross margin	\$ 446,984	\$ 424,452	\$ 22,532	5.3 %
Gross margin percentage	31.6 %	31.8 %		
Branch and regional administrative expenses	273,967	267,283	6,684	2.5 %
Field contribution	\$ 173,017	\$ 157,169	\$ 15,848	10.1 %
Field contribution margin	12.2 %	11.8 %		
Corporate expenses	\$ 84,735	\$ 105,984	\$ (21,249)	-20.0 %
As a percentage of revenue	6.0 %	7.9 %		
Operating loss	\$ (21,221)	\$ (437,818)	\$ 416,597	-95.2 %
As a percentage of revenue	-1.5 %	-32.8 %		

27

The following tables summarize our key performance measures by segment for the nine-month periods indicated:

PDS
For the nine-month periods ended

<i>(dollars and hours in thousands)</i>	September 30, 2023	October 1, 2022	Change	% Change
Revenue	\$ 1,135,365	\$ 1,053,835	\$ 81,530	7.7 %
Cost of revenue, excluding depreciation and amortization	815,221	753,266	61,955	8.2 %
Gross margin	\$ 320,144	\$ 300,569	\$ 19,575	6.5 %
Gross margin percentage	28.2 %	28.5 %		-0.3 % ⁽⁴⁾
Hours	29,738	28,868	870	3.0 %
Revenue rate	\$ 38.18	\$ 36.51	\$ 1.67	4.7 % ⁽¹⁾
Cost of revenue rate	\$ 27.41	\$ 26.09	\$ 1.32	5.2 % ⁽²⁾
Spread rate	\$ 10.77	\$ 10.41	\$ 0.36	3.5 % ⁽³⁾

HHH

For the nine-month periods ended

<i>(dollars and admissions/episodes in thousands)</i>	September 30, 2023	October 1, 2022	Change	% Change
Revenue	\$ 164,525	\$ 177,858	\$ (13,333)	-7.5 %
Cost of revenue, excluding depreciation and amortization	87,189	98,933	(11,744)	-11.9 %
Gross margin	\$ 77,336	\$ 78,925	\$ (1,589)	-2.0 %
Gross margin percentage	47.0 %	44.4 %		2.6 % ⁽⁴⁾
Home health total admissions ⁽⁵⁾	30.9	38.0	(7.1)	-18.7 %
Home health episodic admissions ⁽⁶⁾	21.8	23.3	(1.5)	-6.4 %
Home health total episodes ⁽⁷⁾	34.2	37.5	(3.3)	-8.8 %
Home health revenue per completed episode ⁽⁸⁾	\$ 3,022	\$ 2,978	\$ 44	1.5 %

MS

For the nine-month periods ended

<i>(dollars and UPS in thousands)</i>	September 30, 2023	October 1, 2022	Change	% Change
Revenue	\$ 116,478	\$ 104,805	\$ 11,673	11.1 %
Cost of revenue, excluding depreciation and amortization	66,974	59,847	7,127	11.9 %
Gross margin	\$ 49,504	\$ 44,958	\$ 4,546	10.1 %
Gross margin percentage	42.5 %	42.9 %		-0.4 % ⁽⁴⁾

Unique patients served ("UPS")		258		237		21	8.9 %
Revenue rate	\$	451.47	\$	442.22	\$	9.25	2.2 % ⁽¹⁾
Cost of revenue rate	\$	259.59	\$	252.52	\$	7.07	3.0 % ⁽²⁾
Spread rate	\$	191.88	\$	189.70	\$	2.18	1.2 % ⁽³⁾

(1) Represents the period over period change in revenue rate, plus the change in revenue rate attributable to the change in volume.

(2) Represents the period over period change in cost of patient services rate, plus the change in cost of patient services rate attributable to the change in volume.

(3) Represents the period over period change in spread rate, plus the change in spread rate attributable to the change in volume.

(4) Represents the change in margin percentage year over year.

(5) Represents home health episodic and fee-for-service admissions.

(6) Represents home health episodic admissions.

(7) Represents episodic admissions and recertifications.

(8) Represents Medicare revenue per completed episode.

The following discussion of our results of operations should be read in conjunction with the foregoing tables summarizing our consolidated results of operations and key performance measures, as well as our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Summary Operating Results

Operating Loss

28

Operating loss was \$21.2 million for the nine-month period ended September 30, 2023, as compared to operating loss of \$437.8 million for the nine-month period ended October 1, 2022, a decrease of \$416.6 million, or 95.2%, primarily driven by a \$365.1 million decrease in non-cash charges for goodwill impairment recorded in the comparative nine-month period.

Operating loss for the first nine months of 2023 was positively impacted by an increase of \$15.8 million, or 10.1%, in Field contribution as compared to the first nine months of 2022. The \$15.8 million increase in Field contribution resulted from a \$79.9 million, or 6.0%, increase in consolidated revenue and a 0.4% increase in our Field contribution margin to 12.2% for the first nine months of 2023 from 11.8% for the first nine months of 2022. The primary driver of our higher Field contribution margin year over year was a 0.7% decrease in branch and regional administrative expenses as a percentage of revenue to 19.3% for the first nine months of 2023 from 20.0% for the first nine months of 2022.

In addition to the \$15.8 million increase in Field contribution, the following additional items primarily contributed to the overall \$416.6 million increase in operating income over the comparable periods:

- the \$365.1 million decrease in non-cash charges for goodwill impairment;
- a \$21.2 million decrease in corporate expenses;
- a \$8.5 million increase in other operating income (expense); and
- a \$6.3 million decrease in depreciation and amortization.

Net Loss

Net loss for the nine-month period ended September 30, 2023 was \$108.8 million, as compared to net loss of \$424.3 million for the nine-month period ended October 1, 2022. The \$315.5 million decrease in net loss was primarily driven by

the following:

- the previously discussed \$416.6 million increase in operating income; offset by
- a \$39.9 million increase in interest expense, net of interest income; and
- an aggregate \$59.4 million decrease in valuation gains on interest rate derivatives, net of increases in net settlement received from interest rate derivative counterparties over the comparable year to date periods.

Revenue

Revenue was \$1,416.4 million for the nine-month period ended September 30, 2023, as compared to \$1,336.5 million for the nine-month period ended October 1, 2022, an increase of \$79.9 million, or 6.0%. This increase resulted from the following segment activity:

- an \$81.5 million, or 7.7%, increase in PDS revenue;
- a \$13.3 million, or 7.5%, decrease in HHH revenue; and
- an \$11.7 million, or 11.1%, increase in MS revenue.

Our PDS segment revenue growth of \$81.5 million, or 7.7%, for the nine-month period ended September 30, 2023 was attributable to a 3.0% increase in volume and a 4.7% increase in revenue rate. The 3.0% increase in volume was primarily attributable to growth in demand for non-clinical services.

The 4.7% increase in PDS revenue rate for the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022, resulted primarily from reimbursement rate increases issued by various state Medicaid programs and Managed Medicaid payers.

Our HHH segment revenue decline of \$13.3 million, or 7.5%, for the nine-month period ended September 30, 2023 resulted primarily from a decline in volumes over the comparable period.

The \$11.7 million, or 11.1%, increase in MS segment revenue for the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022, was attributable to volume growth of 8.9% combined with a 2.2% increase in revenue rate over the comparable period.

Cost of Revenue, Excluding Depreciation and Amortization

Cost of revenue, excluding depreciation and amortization, was \$969.4 million for the nine-month period ended September 30, 2023, as compared to \$912.0 million for the nine-month period ended October 1, 2022, an increase of \$57.3 million, or 6.3%. This increase resulted from the following segment activity:

29

- a \$62.0 million, or 8.2%, increase in PDS cost of revenue;
- a \$11.7 million, or 11.9%, decrease in HHH cost of revenue; and
- a \$7.1 million, or 11.9%, increase in MS cost of revenue.

The 8.2% increase in PDS cost of revenue for the nine-month period ended September 30, 2023 resulted from the previously described 3.0% increase in PDS volume combined with a 5.2% increase in PDS cost of revenue rate. The 5.2% increase in cost of revenue rate primarily resulted from higher caregiver labor costs including pass-through of state reimbursement rate increases.

The 11.9% decrease in HHH cost of revenue for the nine-month period ended September 30, 2023 was driven primarily by a decline in HHH volumes, offset in part by increases in overall caregiver costs as a percentage of revenue.

The 11.9% increase in MS cost of revenue for the nine-month period ended September 30, 2023 was driven by the previously described 8.9% growth in MS volumes and a 3.0% increase in cost of revenue rate.

Gross Margin and Gross Margin Percentage

Gross margin was \$447.0 million, or 31.6% of revenue, for the nine-month period ended September 30, 2023, as compared to \$424.5 million, or 31.8% of revenue, for the nine-month period ended October 1, 2022. Gross margin increased \$22.5 million, or 5.3%, from the comparable prior year quarter. The 0.2% decrease in gross margin percentage for the nine-month period ended September 30, 2023 resulted from the combined changes in our revenue rates and cost of revenue rates in each of our segments, which we refer to as the change in our spread rate, as follows:

- a 3.5% increase in PDS spread rate from \$10.41 to \$10.77 driven by the 4.7% increase in PDS revenue rate, net of the 5.2% increase in PDS cost of revenue rate;
- a 1.2% increase in MS spread rate from \$189.70 to \$191.88 driven by the 2.2% increase in MS revenue rate, net of the 3.0% increase in MS cost of revenue rate; and
- our HHH segment, in which gross margin percentage increased by 2.6%.

Branch and Regional Administrative Expenses

Branch and regional administrative expenses were \$274.0 million, or 19.3% of revenue, for the nine-month period ended September 30, 2023, as compared to \$267.3 million, or 20.0% of revenue, for the nine-month period ended October 1, 2022, an increase of \$6.7 million, or 2.5%.

The 2.5% increase in branch and regional administrative expenses was lower than our 6.0% revenue growth for the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022, primarily due to lower integration costs in the current year, as the integration of the 2021 HHH Acquisitions was completed in the second half of 2022, and the positive effects of restructuring portions of our branch and regional operating structure. These factors have resulted in the overall 0.7% decrease in branch and regional administrative expenses as a percentage of revenue during the comparable nine-month periods.

Field Contribution and Field Contribution Margin

Field contribution was \$173.0 million, or 12.2% of revenue, for the nine-month period ended September 30, 2023, as compared to \$157.2 million, or 11.8% of revenue, for the nine-month period ended October 1, 2022. Field contribution increased \$15.8 million, or 10.1%, for the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022. The 0.4% increase in Field contribution margin for the nine-month period ended September 30, 2023 resulted from the following:

- the 0.2% decrease in gross margin percentage in the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022; and
- a 0.7% decrease in branch and regional administrative expenses as a percentage of revenue in the nine-month period ended September 30, 2023, as compared to the nine-month period ended October 1, 2022.

Field contribution and Field contribution margin are non-GAAP financial measures. See “Non-GAAP Financial Measures” below.

Corporate Expenses

Corporate expenses as a percentage of revenue for the nine-month periods ended September 30, 2023 and October 1, 2022 were as follows:

30

(dollars in thousands)	For the nine-month periods ended			
	September 30, 2023		October 1, 2022	
	Amount	% of Revenue	Amount	% of Revenue
Revenue	\$ 1,416,368		\$ 1,336,498	
Corporate expense components:				
Compensation and benefits	\$ 46,642	3.3 %	\$ 49,070	3.7 %
Non-cash share-based compensation	7,179	0.5 %	10,607	0.8 %
Professional services	13,275	0.9 %	25,310	1.9 %
Rent and facilities expense	9,282	0.7 %	9,869	0.7 %
Office and administrative	1,217	0.1 %	2,749	0.2 %
Other	7,140	0.5 %	8,379	0.6 %
Total corporate expenses	\$ 84,735	6.0 %	\$ 105,984	7.9 %

Corporate expenses were \$84.7 million, or 6.0% of revenue, for the nine-month period ended September 30, 2023, as compared to \$106.0 million, or 7.9% of revenue, for the nine-month period ended October 1, 2022. The \$21.2 million, or 20.0%, decrease in corporate expenses resulted primarily from:

- lower compensation and benefits costs due to a reduction in transition and integration activities with acquired businesses, as well as the executive transition completed on December 31, 2022;
- lower non-cash share-based compensation costs due to certain forfeitures of unvested awards and the absence of expense from vesting of pre-IPO awards which were fully expensed during fiscal year 2022; and
- lower professional service costs due to a reduction in transition and integration activities.

Goodwill Impairment

Goodwill impairment was \$105.1 million for the nine-month period ended September 30, 2023. As a result of anticipated volume not being actualized to forecasted levels in the reporting unit within our HHH segment, primarily related to continued challenges in the labor markets, we recorded a \$105.1 million non-cash goodwill impairment charge during the nine months ended September 30, 2023. We recorded a goodwill impairment of \$470.2 million in the comparable period ended October 1, 2022. Please see Note 4 -Goodwill, to the interim unaudited consolidated financial statements, contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Depreciation and Amortization

Depreciation and amortization was \$10.5 million for the nine-month period ended September 30, 2023, as compared to \$16.8 million for the nine-month period ended October 1, 2022, a decrease of \$6.3 million, or 37.4%. The \$6.3 million decrease primarily resulted from the absence of amortization charges associated with assets acquired in connection with

the acquisition of Comfort Care and Accredited completed in the fourth quarter of 2021 which were amortized over a one year period.

Other Operating Income (Expense)

Other operating income was \$6.6 million for the nine-month period ended September 30, 2023, as compared to other operating expense of \$2.0 million for the nine-month period ended October 1, 2022, an increase of \$8.5 million. The \$8.5 million increase primarily resulted from a \$5.1 million non-cash gain on the acquisition of certain business licenses and other net assets recorded during the third quarter of 2023 and a release of reserve of \$3.6 million related to the settlement of a legal matter resulting from a 2020 acquisition.

Interest Expense, net of Interest Income

Interest expense, net of interest income was \$113.3 million for the nine-month period ended September 30, 2023, as compared to \$73.4 million for the nine-month period ended October 1, 2022, an increase of \$39.9 million, or 54.4%. The increase was primarily driven by significant increases in interest rates, largely because the Federal Reserve Board has significantly increased the U.S. federal funds rate since the beginning of 2022. See further analysis under *Liquidity and Capital Resources* below.

Other Income

Other income was \$27.1 million for the nine-month period ended September 30, 2023, as compared to other income of \$86.5 million for the nine-month period ended October 1, 2022, a decrease of \$59.4 million. We realized a \$87.1 million decrease in non-cash valuation gains on interest rate derivatives resulting from changes in market expectations of future interest rates as of the comparable quarter-end

31

valuation dates; offset by an \$27.8 million improvement in net settlements with interest rate derivative counterparties as interest rates increased compared to the prior year period. Details of other income included the following:

(dollars in thousands)	For the nine-month periods ended	
	September 30,	
	2023	October 1, 2022
Valuation gain to state interest rate derivatives at fair value	\$ 2,584	\$ 89,634
Net settlements received from (paid to) interest rate derivative counterparties	24,279	(3,568)
Other	261	457
Total other income	\$ 27,124	\$ 86,523

Income Taxes

We incurred income tax expense of \$1.4 million for the nine-month period ended September 30, 2023, as compared to income tax benefit of \$0.4 million for the nine-month period ended October 1, 2022 April 1, 2023. This increase in tax expense was primarily driven by the changes in federal and state valuation allowances, and changes to federal and state current tax expense. expense and the changes in federal and state valuation allowances.

23

Non-GAAP Financial Measures

In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), which we have discussed above, we also evaluate our financial performance using EBITDA, Adjusted EBITDA, Field contribution and Field contribution margin.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with U.S. GAAP, such as net (loss) income. loss. Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net (loss) income loss before interest expense, net; income tax (expense) benefit; expense; and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; COVID-19 related costs; restructuring costs; other legal matters; other system transition costs, professional fees; and other costs including gains and losses on acquisitions and dispositions of certain businesses. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.

Management believes our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, management considers both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which management does not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.

We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides management a normalized view of our core, ongoing operations after integrating our acquired companies, which is an important measure in assessing our performance.

Given our determination of adjustments in arriving at our computations of EBITDA and Adjusted EBITDA, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to

net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with U.S. GAAP.

32

The following table reconciles net (loss) income loss to EBITDA and Adjusted EBITDA for the periods indicated:

	For the three-month periods ended		For the nine-month periods ended		For the three-month periods ended	
	September 30, 2023	October 1, 2022	September 30, 2023	October 1, 2022	March 30, 2024	April 1, 2023
(dollars in thousands)						
Net (loss) income	(102,389)	24,298	(108,788)	(424,255)		
Net loss					\$ (11,172)	\$ (31,998)
Interest expense, net	39,549	28,298	113,304	73,376	39,545	35,883
Income tax expense (benefit)	631	(2,669)	1,387	(416)		
Income tax expense					12,662	1,566
Depreciation and amortization	2,962	4,917	10,494	16,774	2,912	4,041
EBITDA	(59,247)	54,844	16,397	(334,521)	43,947	9,492
Goodwill, intangible and other long-lived asset impairment	106,841	2,108	107,222	472,192	2,320	68
Non-cash share-based compensation	5,116	3,512	10,144	14,108	4,081	2,442
Interest rate derivatives ⁽¹⁾	(14,120)	(45,038)	(26,865)	(86,066)	(17,918)	11,922
Acquisition-related costs ⁽²⁾	428	-	465	69	-	70

Integration costs (3)	3,26	16,4				
	497	6	1,732	93	299	1,133
Legal costs and settlements associated with acquisition matters (4)	346	876	(4,79 6)	3,38 5	402	304
COVID-related costs, net of reimbursement (5)	-	-	-	5,08 7		
Restructuring (6)	2,14	2,14				
	985	9	5,733	9		
Other legal matters (7)			(5,00 0)	-		
Other system transition costs, professional fees and other (8)	(4,65 5)	3,03 0	(4,50 5)	6,76 8		
Total adjustments (9)	95,43	(30,	84,13	434,		
	\$ 8	\$ 097)	\$ 0	\$ 185		
Restructuring (5)					1,470	2,127
Other legal matters (6)					1,095	-
Other system transition costs, professional fees and other (7)					(813)	923
Total adjustments (8)					\$ (9,064)	\$ 18,989
Adjusted EBITDA	36,19	24,7	100,5	99,6		
	\$ 1	\$ 47	\$ 27	\$ 64	\$ 34,883	\$ 28,481

(1) Represents valuation adjustments and settlements associated with interest rate derivatives that are not included interest expense, net. Such items are included in other income.

- (2) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, and finance and accounting diligence and documentation, as presented on the Company's consolidated statements of operations.
- (3) Represents (i) costs associated with our Integration Management Office, which focuses on our integration efforts and transformational projects such as systems conversions and implementations, material cost reduction and restructuring projects, among other things, of \$0.3 million and \$1.1 million \$0.4 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$0.6 million and \$2.3 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively; and (ii) transitional costs incurred to integrate acquired companies into our field and corporate operations of \$0.2 million \$0.0 million and \$0.6 million \$0.7 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$1.0 million and \$14.2 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively. Transitional costs incurred to integrate acquired companies include IT consulting costs and related integration support costs; salary, severance and retention costs associated with duplicative acquired company personnel until such personnel are exited from the Company; accounting, legal and consulting costs; expenses and impairments related to the closure and consolidation of overlapping markets of acquired companies, including lease termination and relocation costs; costs associated with terminating legacy acquired company contracts and systems; and one-time costs associated with rebranding our acquired companies and locations to the Aveanna brand.
- (4) Represents legal and forensic costs, as well as settlements associated with resolving legal matters arising during or as a result of our acquisition-related activities. This primarily includes (i) costs of \$0.0 million \$0.4 million and \$0.1 million \$0.1 million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$0.8 million and \$3.1 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively, to comply with the U.S. Department of Justice, Antitrust Division's grand jury subpoena related to nursing wages and hiring activities in certain of our markets, in connection with a terminated transaction, and (ii) release of reserve of \$3.6 million for the nine-month periods ended September 30, 2023, related to the settlement of a legal matter resulting from a 2020 acquisition. transaction.
- (5) Represents costs incurred as a result of the COVID-19 environment, primarily including, but not limited to, (i) relocation vaccine, and hero pay provided to our caregivers; staffing and retention related incentives to attract and retain caregivers in the midst of the Omicron surge; and other incremental compensation costs; (ii) sick leave for our caregivers required by OSHA's Emergency Temporary Standard, costs required to comply with federal, state and local vaccination mandates and testing requirements, and worker compensation costs for mandated quarantine time; (iii) incremental PPE costs; and (iv) salary, severance and lease termination costs associated with workforce reductions necessitated by COVID-19; net of temporary reimbursement rate increases provided by certain state Medicaid and Medicaid Managed Care programs.

- (6) Represents costs associated with restructuring our branch and regional administrative footprint as well as our corporate overhead infrastructure costs for the three and nine-month periods ended September 30, 2023, in order to appropriately size our resources to current volumes, including: (i) branch and regional salary and severance costs; corporate salary and severance costs; and (iii) rent and lease termination costs associated with the closure of certain office locations. Restructuring costs also include compensation, severance and related benefits costs associated with an executive transition plan initiated in the first quarter of 2024.
- (7) Represents adjustments activity related to an accrued legal settlement settlements and the related costs and expenses associated with a certain judgment judgments and arbitration awards rendered against the Company related to a certain litigation matter where certain insurance coverage is in Texas. dispute.
- (8) Represents (i) costs associated with the implementation of, and transition to, new electronic medical record system billing and collection systems, duplicative system costs while such transformational projects are in-process, and other

system transition costs of \$0.6 million and \$1.3 million \$0.7 million for the three and nine-month three-month periods ended September 30, 2023 April 1, 2023, respectively, and \$2.2 million and \$5.4 million for the three and nine-month periods ended October 1, 2022, respectively, there were no such costs incurred in the three-month period ended July 2023, March 30, 2024; (ii) a \$5.1 million non-cash gain on professional fees associated with preparation for Sarbanes Oxley compliance of \$0.5 million for the acquisition of certain business licenses and other net assets in the three and nine-month periods three-month period ended September 30, 2023 April 1, 2023, there were no such gains expenses recorded in any other periods, and during the three-month-period ended March 30, 2024; (iii) other costs or (income) that are either non-cash or non-core to the Company's ongoing operations of \$(0.2) \$(0.8) million and \$(0.8) \$(0.8) million for the three and nine-month three-month periods ended September 30, 2023, respectively, March 30, 2024 and \$0.8 million and \$1.4 million for the three and nine-month periods ended October 1, 2022 April 1, 2023, respectively.

(9) (8) The table below reflects the increase or decrease, and aggregate impact, to the line items included in our consolidated statements of operations based upon the adjustments used in arriving at Adjusted EBITDA from EBITDA for the periods indicated:

	Impact to Adjusted EBITDA				Impact to Adjusted EBITDA			
	For the three-month periods ended		For the nine-month periods ended					
					For the three-month periods ended			
	September 30, 2023	October 1, 2022	September 30, 2023	October 1, 2022	March 30, 2024		April 1, 2023	
(dollars in thousands)								
Revenue	\$ -	\$ -	\$ -	\$ -				
Cost of revenue, excluding depreciation and amortization	166	675	(4,512)	5,850	\$ 95		\$ 145	
Branch and regional administrative expenses	2,765	3,947	6,129	7,512	1,312		1,641	
Corporate expenses	4,445	8,299	10,629	35,117	5,378		4,874	
Goodwill impairment	105,136	-	105,136	470,207				
Acquisition-related costs	428	-	465	69	-		70	
Other operating (income) expense	(5,090)	2,121	(8,735)	1,952				

Other income	(12,412)	(45,139)	(24,982)	(86,522)		
Other operating expense					2,320	-
Other income (expense)					(18,169)	12,259
Total adjustments	95,438	(30,097)	84,130	434,185	(9,064)	18,989

Field Contribution and Field Contribution Margin

Field contribution and Field contribution margin are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with U.S. GAAP, such as gross margin and gross margin percentage. Rather, we present Field contribution and Field contribution margin as supplemental measures of our performance. We define Field contribution as gross margin less branch and regional administrative expenses. Field contribution margin is Field contribution as a percentage of revenue. As non-GAAP financial measures, our computations of Field contribution and Field contribution margin may vary from similarly termed

25

non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of these measures impracticable.

Field contribution and Field contribution margin have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to gross margin, gross margin percentage, net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with U.S. GAAP.

Management believes Field contribution and Field contribution margin are helpful in highlighting trends in our core operating performance and evaluating trends in our branch and regional results, which can vary from year to year. We use Field contribution and Field contribution margin to make business decisions and assess the operating performance and results delivered by our core field operations, prior to corporate and other costs not directly related to our field operations. These metrics are also important because they guide us in determining whether or not our branch and regional administrative expenses are appropriately sized to support our caregivers

34

and direct patient care operations. Additionally, Field contribution and Field contribution margin determine how effective we are in managing our field supervisory and administrative costs associated with supporting our provision of services and sale of products.

The following table reconciles gross margin to Field contribution and Field contribution margin for the periods indicated:

	For the three-month periods ended		For the nine-month periods ended		For the three-month periods ended	
	Septe mber 30, 2023	Octo ber 1, 2022	Septe mber 30, 2023	Octo ber 1, 2022	March 30, 2024	April 1, 2023
<i>(dollars in thousands)</i>						
Gross margin	147,264	134,583	446,984	424,452	\$ 145,854	\$ 144,465
Gross margin percentage	30.8%	30.4%	31.6%	31.8%	29.7%	31.0%
Branch and regional administrative expenses	91,004	89,542	273,967	267,283	87,914	91,708
Field contribution	56,260	45,041	173,017	157,169	\$ 57,940	\$ 52,757
Field contribution margin	11.8%	10.2%	12.2%	11.8%	11.8%	11.3%
Revenue	478,010	443,009	1,416,368	6,498	\$ 490,653	\$ 466,413

Liquidity and Capital Resources

Overview

Our principal sources of cash have historically been from cash provided by operating activities. Our principal source of liquidity in addition to cash provided by operating activities, or when we have used net cash in our operating activities, has historically been from proceeds from our credit facilities and issuances of common stock.

Our principal uses of cash and liquidity have historically been for acquisitions, interest and principal payments under our credit facilities, payments under our interest rate derivatives, and financing of working capital. Payment of interest and related fees under our credit facilities is currently the most significant use of our operating cash flow. Our goal is to use cashflow provided by operations primarily as a source of cash to supplement the purchase price for acquisitions.

In March 2023, in connection with a \$19.8 million legal judgment rendered against us, we posted an \$18.4 million appellate bond with the court. The \$18.4 million appellate bond was collateralized with \$15.0 million of letters of credit and \$3.4 million of cash collateral. In July 2023, we reached a confidential settlement agreement with the plaintiffs to release all claims and extinguish the aforementioned judgment in exchange for a settlement payment covered by our insurance policy. During the quarter ended September 30, 2023, we secured the return of the \$15.0 million of letters of credit and \$3.4 million of cash collateral.

In September 2023, in response to a \$7.9 million arbitration award rendered against us in connection with a civil litigation matter, we promptly obtained a \$9.1 million appellate bond with the trial court. The \$9.1 million appellate bond was collateralized with letters of credit. While we intend to avail ourselves of all appellate options, the resolution of this matter could reduce the cash available to us for general working capital purposes.

In connection with a settlement agreement we entered into in March 2023 with the sellers of Epic/Freedom LLC and other defendants (collectively, the "Defendants"), we funded \$6.8 million in April 2023 to an escrow account for the purposes of settling certain tax audits with the IRS, which are currently under appeal with the IRS. At such time as the audits are concluded, these escrowed funds will be used to satisfy any additional amounts due to the IRS or paid to the Seller. To the extent that any additional amounts due to the IRS exceed the escrowed funds, we as the taxpayer, will be required to fund such amounts, but we have contractual rights to reimbursement from the Defendants. We expect these tax matters to conclude in the fourth quarter of fiscal year 2023 or the first half of fiscal year 2024.

For additional information with respect to the foregoing litigation matters, please see "*Litigation and Other Current Liabilities*" set forth in Note 11.10 to our interim unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q.

On February 21, 2024, Change Healthcare, a subsidiary of UnitedHealth Group that acts as an intermediary for processing certain payment claims we submit through certain third-party revenue cycle management solutions for payors ("third-party vendors"), notified our third-party vendors of a cybersecurity incident. In response to the incident, both our third-party vendors and Change Healthcare severed the service connections between their respective systems. The Change Healthcare incident did not materially affect our operations, except our ability to submit payment claims through these particular third-party vendors for a short period of time while we sought alternative claims submission arrangements. The incident did not materially increase our patient accounts receivable balances nor decrease our Net cash (used in) provided by operating activities for the first quarter of 2024.

At September 30, 2023 March 30, 2024 we had \$48.3 million \$42.6 million in cash on hand, \$20.0 million \$10.0 million available to us under our Securitization Facility and approximately \$168.0 million \$168.2 million of borrowing capacity under the Revolving Credit Facility. Available borrowing capacity under the Revolving Credit Facility is subject to a maintenance

leverage covenant that becomes effective if more than 30% of the total commitment is utilized, subject to a \$15.0 million carve-out for letters of credit. We believe that our operating cash flows, available cash on hand, and availability under our Securitization Facility and Revolving Credit Facility will be sufficient to meet our cash requirements for at

26

least the next twelve months. Our future capital requirements will depend on many factors that are difficult to predict, including the size, timing and structure of any future acquisitions, future capital investments and future results of operations. We cannot assure you that cash provided by operating activities or cash and cash equivalents on hand will be sufficient to meet our future needs. If we are unable to generate sufficient cash flows from operations in the future, we may have to obtain additional financing. If we obtain additional capital by issuing equity, the interests of our existing stockholders will be diluted. If we incur additional indebtedness, that indebtedness

35

may contain significant financial and other covenants that may significantly restrict our operations. We cannot assure you that we could obtain refinancing or additional financing on favorable terms or at all.

Cash Flow Activity

The following table sets forth a summary of our cash flows from operating, investing, and financing activities for the nine-month three-month periods presented:

	For the nine-month periods ended		For the three-month periods ended	
	September 30, 2023	October 1, 2022	March 30, 2024	April 1, 2023
(dollars in thousands)				
Net cash provided by (used in) operating activities	\$ 25,677	\$ (8,166)		
Net cash (used in) provided by operating activities			\$ (11,972)	\$ 7,495
Net cash used in investing activities	\$ (7,226)	\$ (22,092)	\$ (1,308)	\$ (4,800)
Net cash provided by financing activities	\$ 10,626	\$ 63,449	\$ 11,945	\$ 12,521

Operating Activities

The primary sources or uses of our operating cash flow are operating income or operating losses, as well as any other significant non-cash items such as depreciation, amortization and share-based compensation, and cash paid for interest. The timing of collections of accounts receivable and the payment of accounts payable, other accrued liabilities and accrued payroll can also impact and cause fluctuations in our operating cash flow. Cash used by operating activities increased by \$33.8 million during \$19.5 million for the nine-month three-month period ended September 30, 2023 March 30, 2024 compared to the nine-month three-month period ended October 1, 2022 April 1, 2023, primarily due to:

- the provision of cash associated with operating assets and liabilities over the comparable periods, period, include the timing of payroll and incentive settlements, the deferral prior year benefit of deferring of one month of interest under our term loans which we typically pay had previously paid on a monthly basis, and the prior year benefit one-time deferral of cash payments under employee medical plans as we transitioned to a self-insured plan, partially offset by
- improvements in operating income over the prior year period.

Days Sales Outstanding ("DSO")

DSO provides us with a gauge to measure the timing of cash collections against accounts receivable and related revenue. DSO is derived by dividing our average patient accounts receivable for the fiscal period by our average daily revenue for the fiscal period. The collection cycle for our HHH segment is generally longer than that of our PDS segment, primarily due to longer billing cycles for HHH, which is generally billed in thirty day increments. The following table presents our trailing five quarter DSO for the respective periods:

	October 1, 2022	December 31, 2022	April 1, 2023	July 1, 2023	September 30, 2023
Days Sales Outstanding	47.8	44.5	45.2	46.2	45.0

	April 1, 2023	July 1, 2023	September 30, 2023	December 30, 2023	March 30, 2024
Days Sales Outstanding	45.2	46.2	45.0	44.9	45.8

Investing Activities

Net cash used in investing activities was \$7.2 million \$1.3 million for the nine-month three-month period ended September 30, 2023 March 30, 2024, as compared to \$22.1 million \$4.8 million for the nine-month three-month period ended October 1, 2022 April 1, 2023. The primary driver of the \$14.9 million \$3.5 million decrease in cash used in the current period was the \$11.7 million premium paid for an interest rate cap in February 2022. prior year purchase of certificates of need of \$2.7 million.

Financing Activities

Net cash provided by financing activities decreased by \$52.8 million \$0.6 million, from \$63.4 million \$12.5 million net cash provided for the nine-month three-month period ended October 1, 2022 April 1, 2023 to \$10.6 million \$11.9 million for the nine-month three-month period ended September 30, 2023 March 30, 2024. The \$52.8 million \$0.6 million decrease was primarily attributable to:

- a \$14.0 million increase in cash inflows from settlements with interest rate swap counterparties over the compar periods; offset by
- a comparable decrease of \$64.7 million in net to lower borrowings under our the Securitization Facility Revol Credit Facility and term loans over during the comparable periods.

three-month period ended March 30, 2024.

Indebtedness

We typically incur term loan indebtedness to finance our acquisitions, and we borrow under our Securitization Facility and Revolving Credit Facility from time to time for working capital purposes, as well as to finance acquisitions, as needed. The following table presents

36 27

our current and long-term obligations under our credit facilities as of September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, as well as related interest expense for the nine-month three-month periods ended September 30, 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively:

(dollars in thousands)	Current and Long-term		Interest Expense			Current and Long-term		Interest Expense		
			For the nine-month periods ended					For the three-month periods ended		
	Obligations					Obligations				
Instrument	Septe mber 30, 2023	Dece mber 31, 2022	Inte rest e	Septe mber 30, 2023	Septe mber 1, 2022	March 30, 2024	December 30, 2023	Interest Rate	March 30, 2024	April 1, 2023

2021												
Extended			S +									
Term Loan ⁽¹⁾	902,0	908,	3.75	60,75	38,2							
⁽³⁾	\$ 50	\$ 950	%	\$ 0	\$ 37							
2021												
Extended						S +						
Term Loan ⁽¹⁾						\$ 897,450	\$ 899,750	3.75%	\$ 20,977	\$ 19,238		
Term Loan -			S +									
Second Lien	415,0	415,	7.00	38,05	25,3							
Term Loan ⁽¹⁾	00	000	%	5	88	415,000	415,000	7.00%	13,137	12,208		
Revolving			S +									
Credit Facility			3.75									
⁽²⁾	-	-	%	667	716							
Securitization			S +									
Facility ⁽⁴⁾	155,0	140,	3.50		3,38							
	00	000	%	8,909	9							
Revolving												
Credit Facility							S +					
⁽¹⁾						-	-	3.75%	213	253		
Securitization							S +					
Facility ⁽²⁾						165,000	155,000	3.50%	3,683	2,538		
Amortization of debt issuance costs												
	-	-			5,22							
			3,983	1		-	-		1,223	1,421		
Other	-	-	1,178	794		-	-		414	300		
Total	1,46											
Indebtedness	1,472	3,95	113,5	73,7								
	\$,050	\$ 0	\$ 42	\$ 45	\$ 1,477,450	\$ 1,469,750		\$ 39,647	\$ 35,958			
Weighted Average Interest Rate												
⁽⁵⁾	10.0 %	8.9 %										

Weighted
Average
Interest Rate

(3)	10.1 %	10.1 %
-----	--------	--------

- (1) Variable rate debt instruments instrument which accrue accrues interest at a rate equal to the SOFR rate, plus a CS (subject to a minimum of 0.50%), plus an applicable margin.
- (2) Variable rate debt instruments instrument which accrue accrues interest at a rate equal to the SOFR rate, plus a CS plus an applicable margin.
- (3) Interest associated with the 2021 Extended Term Loan includes interest expense and commitment fees of \$5.9 milli in the nine-month period ended October 1, 2022 related to the Delayed Draw Term Loan Facility ("DDTL"). T Company terminated the DDTL commitment in November 2022.
- (4) Variable rate debt instrument which accrues interest at a rate equal to the SOFR rate, plus a CSA, plus an applicable margin,
- (5) Represents the weighted average annualized interest rate based upon the outstanding balances at September : 2023 March 30, 2024 and October 1, 2022 April 1, 2023, respectively, and the applicate applicable interest rates at tl date.

We were in compliance with all financial covenants and restrictions related to existing credit facilities at September 30, 2023.

On February 9, 2022 we entered into a five-year, \$880.0 million notional interest rate cap agreement with a cap rate of 3.0%. The cap agreement expires in February 2027 and provided that the counterparty would pay us the amount by which LIBOR exceeds 3.0% in a given measurement period. During the second quarter of 2023, the Company amended its interest rate cap agreements to provide that the counterparty will pay the Company the amount by which SOFR exceeds 2.96%.

On August 9, 2022, we borrowed \$60.0 million under the Delayed Draw Term Loan Facility to replace cash on our balance sheet previously used to complete acquisitions in the fourth quarter of fiscal year 2021. On November 16, 2022, we terminated the remaining Delayed Draw Term Loan Facility of \$140.0 million March 30, 2024.

On March 23, 2023 we amended the agreement governing our Revolving Credit Facility to increase the sublimit for letters of credit to \$40.0 million from \$30.0 million. The other terms of the Revolving Credit Facility remained unchanged by such amendment.

Due to the phase-out of LIBOR, effective June 30, 2023, the benchmark interest rate under our senior secured credit facilities converted from LIBOR to SOFR, plus an applicable credit spread adjustment ("CSA"). Outstanding balances under our senior secured credit facilities bear interest at SOFR (including the applicable CSA), plus a margin. The margins under our senior secured credit facilities are unchanged as a result of the SOFR conversion.

On July 31, 2023, we amended our Securitization Facility to extend its maturity date from November 12, 2024 to July 31, 2026. The facility accrues interest at a rate equal to the SOFR rate, plus a CSA, plus an applicable margin.

Contractual Obligations

Our contractual obligations consist primarily of long-term debt obligations, interest payments, operating and financing leases. These contractual obligations impact our short-term and long-term liquidity and capital needs. As of September 30, 2023 March 30, 2024, there were no material changes to our contractual obligations from those described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023.

37

Critical Accounting Estimates

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Estimates” and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023 for accounting policies and related estimates we believe are the most critical to understanding our consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include patient services and product revenue; business combinations; goodwill; and insurance reserves. There have been no changes to our critical accounting estimates or their application since the date of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023.

Goodwill

We perform an impairment test for goodwill at least annually or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. We perform our annual goodwill impairment test on the first day of the fourth quarter of each fiscal year for each of our reporting units. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The impairment test is a single-step process. The process requires us to estimate and compare the fair value of a reporting unit to its carrying amount, including goodwill. If the fair value exceeds the carrying amount, the goodwill is not considered impaired. To the extent a reporting unit’s carrying amount exceeds its fair value, the reporting unit’s goodwill is deemed impaired, and an impairment charge is recognized based on the excess of a reporting unit’s carrying amount over its fair value. The fair value of the reporting units is measured using Level 3 inputs such as operating cash flows and market data.

A reporting unit is either an operating segment or one level below the operating segment, referred to as a component. When the components within our operating segments have similar economic characteristics, we aggregate the components of our operating segments into one reporting unit. Since quoted market prices for our reporting units are not available, we apply judgment in determining the fair value of these reporting units for purposes of performing the goodwill impairment test. For both interim and annual goodwill impairment tests, we engage a third-party valuation firm to assist management in calculating a reporting unit’s fair value, which is derived using an income approach or a combination of both income and market approaches. The income approach utilizes projected operating results and cash flows and includes significant assumptions such as revenue growth rates, projected EBITDA margins, and discount rates. The market approach compares reporting units’ earnings and revenue multiples to those of comparable public companies. Estimates of fair value

may differ from actual results due to, among other things, economic conditions, changes to business models or changes in operating performance. These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. Significant differences between these estimates and actual future performance could result in impairment in future fiscal periods.

We performed an interim impairment test during the third quarter of fiscal year 2023 primarily as a result of continued challenges in the labor markets which resulted in anticipated volume not being actualized to forecasted levels in the reporting unit within our HHH segment. While many of our reporting units have a carrying value that is consistent with its fair value due to impairment in five of our six reporting units recorded during the fourth quarter of 2022, our interim impairment test determined that the carrying value of the reporting unit within our HHH segment exceeded its respective fair value and we accordingly recorded an aggregate goodwill impairment charge of \$105.1 million during the three-month period ended September 30, 2023.

We can provide no assurance that our goodwill will not become subject to impairment in any future period.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our principal executive officer, principal financial officer, and principal accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities

28

Exchange Act of 1934 (the "Exchange Act"). Based on this evaluation, our principal executive officer, principal financial officer and principal accounting officer concluded that, as of September 30, 2023 March 30, 2024, such disclosure controls and procedures were not effective, solely as a result of a previously reported material weakness.

38

Notwithstanding the foregoing, there were no changes to previously issued financial statements, and management did not identify any misstatements in our financial statements as a result of this material weakness. Our principal executive officer, principal financial officer, and principal accounting officer believe that the interim unaudited consolidated financial

statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in accordance with U.S. GAAP.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, the material weakness is due to control deficiencies related to the overall information technology general controls ("ITGCs") for both user access and program change management for systems supporting all of the Company's internal control processes and controls, controls over the completeness and accuracy of information used in business process controls and management review controls. Our business process controls (automated and manual), and management review controls were also deemed ineffective because they are adversely impacted by these ineffective ITGCs. Additionally, we did not fully design and implement business process controls (automated and manual) that are dependent on one of the revenue systems in the Private Duty Services segment which has been replaced in fiscal 2024.

As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023, management is in the process of implementing its remediation plan. Our remediation efforts include: (i) implementation of a new revenue system; system in Q1 2024; (ii) changes improvements to our ITGCs in the areas of user access and program change-management for systems supporting all of the Company's internal control processes to ensure that internal controls are designed and operating effectively; and (iii) training and educating the control owners on ITGC policies concerning the principles and requirements of each control, with a focus on those related to user access and change-management over IT systems impacting financial reporting. We believe that these actions will remediate the foregoing material weakness. The material weakness will not be considered remediated, however, until the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Control over Financial Reporting

Except for the actions intended to remediate the material weakness as described above, there were no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the three-month period ended September 30, 2023 March 30, 2024, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer, principal financial officer, and principal accounting officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error

or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls' effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures.

39 29

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

Information in response to this Item is included in “Part I – Item 1 - Note 11 10 – *Commitments and Contingencies*” and is incorporated by reference into this Part II, Item 1 of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

There have been no material changes to the risk factors described in the Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 December 30, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the quarter ended **September 30, 2023** **March 30, 2024**, none of the directors or officers of the Company adopted, modified, or terminated any contract, instruction or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Exchange Act or any "non-Rule 10b5-1 trading arrangement", as defined in Item 408 of Regulation S-K.

Item 6. Exhibits

The following exhibits are filed or furnished herewith:

Exhibit Number	Description
10.1* 10.1	<u>Third Amendment to the Receivables Financing Separation and Transition Agreement, dated July 31, 2023</u>
1	<u>January 15, 2024, by and among Aveanna SPV I, LLC, as borrower, Shannon Drake, Aveanna Healthcare LLC as initial servicer, PNC Bank, National Association, as administrative agent, and PNC Capital Markets LLC, as structuring agent (Aveanna Healthcare Holdings Inc., filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on August 4, 2023) January 17, 2024 and incorporated herein by reference).</u> <u>reference herein.</u>
31.1	<u>Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2	<u>Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.3	<u>Certification of Principal Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1	<u>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2	<u>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.3	<u>Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise discussed in such

40 30

exhibit. The Company will
supplementally provide a
copy of any omitted
schedule or similar
attachment to the U.S.
Securities and Exchange
Commission or its staff
upon request.

41

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Aveanna Healthcare Holdings Inc.

Date: November 9, 2023 May 9, 2024

By: /s/ Jeff Shaner

Jeff Shaner
Chief Executive Officer
(Principal Executive Officer)

Date: May 9, 2024

By: /s/ Matthew Buckhalter
Matthew Buckhalter
Chief Financial Officer
(Principal Financial Officer)

Date: November 9, 2023 May 9, 2024

By: /s/ Deborah Stewart
Deborah Stewart
Chief Accounting Officer
(Principal Accounting Officer)

42 32

Exhibit 31.1

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeff Shaner, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 March 30, 2024 of Aveanna Healthcare Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer officers and I are responsible for establishing and maintaining disclosure controls procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By

Date: November 9, 2023 May 9, 2024

:

/s/ Jeff Shaner

Jeff Shaner

**Chief Executive Officer
(Principal Executive Officer)**

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, **Deborah Stewart**, **Matthew Buckhalter**, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended **September 30, 2023** **March 30, 2024** of Aveanna Healthcare Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying **officer** **officers** and I are responsible for establishing and maintaining disclosure controls procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023 May 9, 2024

By

:

/s/ Matthew Buckhalter

Matthew Buckhalter

Chief Financial Officer

(Principal Financial Officer)

Exhibit 31.3

CERTIFICATION PURSUANT TO

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Deborah Stewart, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2024 of Aveanna Healthcare Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in

material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By

Date: May 9, 2024

:

/s/ Deborah Stewart

Deborah Stewart

**Chief Accounting Officer
(Principal Accounting Officer)**

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Aveanna Healthcare Holdings Inc. (the "Company") on Form 10-Q for the fiscal quarter ended **September 30, 2023** **March 30, 2024**, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeff Shaner, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **November 9, 2023** **May 9, 2024**

By

:

/s/ Jeff Shaner

Jeff Shaner

**Chief Executive Officer
(Principal Executive Officer)**

CERTIFICATION PURSUANT TO

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Aveanna Healthcare Holdings Inc. (the "Company") on Form 10-Q for the fiscal quarter ended **September 30, 2023** March 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Matt Buckhalter, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2024

By:

/s/ Matt Buckhalter

Matt Buckhalter

Chief Financial Officer

(Principal Financial Officer)

Exhibit 32.3

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Aveanna Healthcare Holdings Inc. (the "Company") on Form 10-Q for the fiscal quarter ended March 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Deborah Stewart, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **November 9, 2023** May 9, 2024

By:

/s/ Deborah Stewart

Deborah Stewart
Chief Accounting Officer
(Principal Accounting Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.